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1. BACKGROUND 
1.1. Incidence, survival, mortality, and prevalence 
1.1.1. Incidence 
Prostate cancer (PCa) is the most common malignancy among men in Norway. From 2005 to 2009, 
4,100 new cases were diagnosed annually, which represents 29% of all new annual male cancer cases 
(1). During the past two decades, there has been a marked increase in the incidence rate of PCa in 
Norway. From 1984 to 2008, the incidence rate/100,000 person-years (age adjusted to the world’s 
standard population) more than doubled from 44.6 to 99.9. The cumulative risk of developing PCa by 
the age of 75 years for Norwegian men is 12.4% (i.e., one in eight men) (1). 
 Internationally, there has also been a considerable increase in the incidence of PCa during 
recent decades, especially in developed countries. One important reason for this increase is the use of 
prostate-specific antigen (PSA) blood tests, which became available in 1980 in the United States and 
from the early 1990s in Norway (2). However, a minor increase in the incidence rate of PCa was 
observed in the period before the PSA test was introduced and was attributed mainly to the aging of 
the male population in general and the increased attention given to cancer diagnosed after surgical 
treatment for benign hyperplasia of the prostate (2;3). 
1.1.2. Survival 
The 5-year relative overall survival of PCa patients in Norway for the last reported period, 2005–2009, 
was 87% compared with 50% in the period 1970–1974 (1). This indicates that the prognosis for PCa in 
general is good. However, 20% of patients have metastatic disease at diagnosis, and the 5-year relative 
overall survival for these patients is 31%. For localized PCa, the 5-year relative overall survival is 
currently 97%. However, the long-term survival among patients diagnosed younger than age 50 years 
is poorer than for patients diagnosed at age 50–59 years. Reasons for this difference are that the 
younger age group has more aggressive tumors and that there is greater use of PSA screening in the 
older age group.  
1.1.3. Mortality rate 
PCa-specific mortality rates reflect the number of patients per 100,000 people who die each year from 
PCa. From a global perspective, PCa is the second most frequent cause of cancer death among men in 
the developed world. A slight increase in the number of deaths from PCa was observed from 1985 to 
the late 1990s in most countries, even in those countries or regions where PCa was rare. Since the late 
1990s, a reduction in mortality has been observed globally and in Norway (4;5). The reasons for this 
reduction in mortality have been the subject of discussion, particularly in relation to whether the 
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decrease is attributable to the increased use of PSA testing, leading to earlier diagnosis, and/or 
increased use of curative treatment (3). Conflicting data for PSA screening trials have been reported in 
North American and European studies. In one European trial, PCa mortality was reduced by 27% after 
9 years and 44% after 14 years of follow-up after PSA screening (6-8). By contrast, data from a North 
American PSA screening trial showed no mortality benefit from PSA screening at 7–10 years’ follow-
up, and this was confirmed by recently published data for the 13-year follow-up (9). A Swedish 
substudy showed that, to prevent one death from PCa, 293 men needed to be screened and 12 treated 
for PCa compared with unscreened and untreated controls (8). These studies show that the differences, 
if any, in PCa mortality between screened and unscreened groups are small. However, at present, we 
cannot exclude the possibility that longer follow-up will change this conclusion, at least for some 
subgroups. 
 Screening for PCa is also controversial because of the costs, psychological effects, and 
uncertain long-term benefits to patients (10). For example, the European Association of Urology 
(EAU), Norwegian heath authorities, and Mayo Clinic guidelines all recommend that PSA tests should 
be performed only after discussion between the patient and his doctor. A recently published review 
concluded that PSA-based screening results in little or no reduction in PCa-specific mortality and is 
associated with harm related to subsequent evaluation and treatment, some of which may be 
unnecessary (11). 
 In Norway, PCa is second to lung cancer as the main cause of cancer-related death among 
men, and more men die from PCa than women die from breast cancer. The mortality rate peaked in the 
mid-1990s (see Figure 1.1) and has been declining since. It is not clear why Norway and the other 
Scandinavian countries have relatively high mortality rates from PCa. Apart from the high incidence, a 
possible explanation is differences in the coding of the causes of death between countries (12). 
 The National Program for Prostate Cancer in Norway (NPPC) was established in 2004, with 
the primary goal of improving survival, reducing mortality and quality of care for PCa patients 
through nationwide documentation of diagnosis, treatment, and progression of PCa. Importantly, the 
program recommends that all relevant data be recorded prospectively in a national database located 
within the Cancer Registry of Norway. 
 The increase in incidence and decrease in mortality over the past 15 years coupled with longer 
life expectancy for Norwegian men mean that the prevalence of PCa is increasing rapidly; at the end of 
2008, 27,570 Norwegian men were living with a prior diagnosis of PCa. 
1.2. Risk factors for the development of PCa 
There are a number of risk factors for the development of PCa. The most importent is older age; by 80 
years, 50% of all men have malignant cells in their prostate. In Norway, the mean general life 
expectancy for men is currently 79 years (13), and the median age at diagnosis is 70 years. Only 3.6% 
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are diagnosed before the age of 55 years, and almost 70% of patients are older than 64 years at 
diagnosis. The number of new cancer cases among men in Norway is expected to increase by about 
40% by 2030 because of population growth and the increased proportion of older people in the 
population (1). 
Figure 1.1. Trends in age-standardized relative survival proportions, incidence, and mortality 
rate from Cancer in Norway, 2009 (1) 
 
 
 The incidence of PCa varies considerably between countries and world regions, and between 
ethnicities within a country. The highest annual incidence rate (185 per 100,000 men) is among 
African-American men, and the lowest incidence (1.7 per 100,000) is among Chinese men (3). 
However, when Japanese men (marry to Japan women) emigrate from Japan to Hawaii, their risk of 
PCa increases and approaches that of US-born men (14) within two generations, suggesting that 
environmental factors are more important than genetic factors. 
 Lifestyle factors including diet, alcohol consumption, sexual activity, exposure to ultraviolet 
radiation, and occupational exposure have all been reported as possible factors of etiological relevance 
(15). Nutritional factors considered as risk factors for the development of PCa include high total 
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energy intake (reflected by body mass index) and intake of dietary fat and cooked meat, all of which 
increase the risk for PCa. Conversely, micronutrients and vitamins (carotenoids, retinoids, and 
vitamins C, D, and E), fruit and vegetable intake, minerals (calcium and selenium), and 
phytoestrogens (isoflavonoids, flavonoids, and lignans) may all reduce the risk of PCa (16;17). 
 Hereditary PCa occurs in a subgroup (about 9%) of individuals with PCa and is identified by 
examination of the pedigree showing three or more affected relatives or at least two relatives who have 
developed early-onset disease before age 55 years (18). Patients with hereditary PCa have disease 
onset 6–7 years earlier, on average, than those with sporadic PCa, but these two patient groups do not 
differ biologically (19). The gene mutations leading to the increased risk of developing hereditary PCa 
have not been identified at the molecular level. However, special interest has been directed toward 
inherited mutations of the tumor suppressor gene breast cancer types 1 and 2 (BRCA1 and 2) because 
male mutant carriers of BRCA2 have an increased risk of PCa, whereas the risk of PCa in men with 
the BRCA1 mutation is not clear (20). 
1.3. Classification of PCa 
In this thesis, the extent of disease is classified according to the sixth version of the tumor–node–
metastasis (TNM) system published in 2002 (21). Clinical staging (designated cTNM) defines the 
anatomical extent of a tumor based on clinical data before initiation of treatment. If the staging is 
based on radiological examination, it is designated rTNM. Pathological staging (designated pTNM) is 
based on examination by pathologists of tissues removed during prostatectomy (pT) or lymph node 
dissection (pN). When considering curatively intended treatment for PCa, an important distinction is 
made between localized (tumor localized to the prostate gland; T1–T2, N0, and M0) and locally
advanced PCa (T3–T4, N0, and M0, where the tumor has grown through the capsule covering the 
prostate gland). 
1.3.1. T stage 
The extent of the primary tumor is assessed based on palpation during digital rectal examination 
(DRE), where the distinction between intracapsular (T1–T2) and extracapsular (T3–T4) PCa has a 
significant impact on treatment decisions and prognosis. Several studies have shown that DRE often 
underestimates tumor extension (22;23). 
 The clinical examination can be supported by various imaging procedures. The most 
commonly used method is transrectal ultrasound (TRUS) examination. However, only 60% of tumors 
are visible with TRUS; the remaining tumors are not distinguishable from normal tissue because of 
their echogenicity. In a large multi-institutional study, TRUS was no more accurate than DRE at 
predicting organ-confined PCa (24;25). Furthermore, neither conventional magnetic resonance 
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imaging (MRI) nor positron emission tomography (PET) accurately predicts extracapsular extension 
of PCa (26;27).
Table 1.1. Tumor–node–metastasis (TNM) classification of PCa 2002 (28) 
T – Primary tumor
 TX  Primary tumor cannot be assessed 
 T0  No evidence of primary tumor 
T1 Clinically undetected tumor not palpable or visible by imaging 
 T1a  Tumor incidental histological finding in 5% or less of tissue resected 
 T1b  Tumor incidental histological finding in more than 5% of tissue resected 
 T1c  Tumor identified by needle biopsy (e.g., because of elevated prostate-specific antigen 
level) 
T2  Tumor confined within the prostate1 
 T2a  Tumor involves one-half of one lobe or less 
 T2b  Tumor involves more than half of one lobe, but not both lobes 
 T2c  Tumor involves both lobes 
T3  Tumor extends through the prostatic capsule2 
 T3a  Extracapsular extension (unilateral or bilateral) 
 T3b  Tumor invades seminal vesicle(s) 
T4  Tumor is fixed or invades adjacent structures other than seminal vesicles: bladder neck, 
external sphincter, rectum, levator muscles, or pelvic wall 
N – Regional lymph nodes3
 NX  Regional lymph nodes cannot be assessed 
 N0  No regional lymph node metastasis 
 N1  Regional lymph node metastasis 
M – Distant metastasis4
 MX  Distant metastasis cannot be assessed 
 M0  No distant metastasis 
 M1  Distant metastasis 
  M1a Nonregional lymph node(s) 
  M1b Bone(s) 
  M1c Other site(s) 
1 Tumor found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is classified as T1c. 
2 Invasion into the prostatic apex or into (but not beyond) the prostate capsule is not classified as T3, but as T2. 
3 Metastasis no larger than 0.2 cm can be designated pN1mi. 
4 When more than one site of metastasis is present, the most advanced category should be used. 
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 The recently updated EAU recommendation states that MRI should not be used in routine 
clinical assessment of the T stage (29). The addition of dynamic contrast-enhanced MRI can be helpful 
in difficult cases. The addition of magnetic resonance spectroscopic imaging to MRI also increases the 
accuracy and decreases interobserver variability in the evaluation of extracapsular extension of PCa 
(30). 
1.3.2. N stage 
According to the EAU, N staging should be performed only when the findings will influence a 
treatment decision. The gold standard for assessing regional lymph node involvement in PCa is pelvic 
lymphadenectomy performed using an open or laparoscopic technique. Patients with tumor stage T2 or 
lower, with a PSA level < 20 g/L and Gleason score  6, have a < 10% likelihood of having lymph 
node metastases and can therefore be spared pelvic lymphadenectomy (31). In the current literature, 
computed tomography (CT) and MRI perform equally well for the detection of pelvic lymph node 
metastases (32). 
1.3.3. M category 
Although PCa metastasizes mainly to bone, metastases can be found in any organ. According to the 
EAU guidelines, bone metastases are best assessed by a technetium bone scan. This type of scan is not 
indicated in asymptomatic patients if the serum PSA level is < 20 g/L and in the presence of well- or 
moderately differentiated tumors (Gleason score  6). Because the scope of this thesis is nonmetastatic 
and curable PCa, the issue of metastatic disease is not discussed further. 
1.4. Histopathology 
The aggressiveness of the malignancy can be identified by a pathologist’s examination of the 
microscopic pattern of the prostate cancer cells. According to the EAU guidelines (31), in patients 
with a glandular volume of 30–40 mL, at least eight biopsies should be taken. The Gleason score is the 
most commonly used system for grading adenocarcinomas of the prostate, and the system has been 
recommended by the World Health Organization since 1993 (33). The Gleason score is the sum of the 
two most common patterns (grades 1–5) of tumor growth found. The Gleason sum score ranges 
between 2 and 10, with 2 being the least aggressive growth pattern and 10 the most aggressive. The 
pathologist assigns a primary grade to the most common tumor pattern and a secondary grade to the 
next most common tumor pattern, and these grades are added. A Norwegian national study by Kvåle et 
al. (34) reported the following distribution of Gleason scores: score 2–4, 4.5%; score 5–6, 65.5%; 
score 7, 25.7%; and score 8–10, 4.3%. 
 Preoperative needle biopsy specimens often yield lower Gleason scores than postoperative 
examination of the prostatectomy specimen. A review of 3,789 cases of PCa from the United States 
 
16
showed that the Gleason score was undergraded in 42% of cases and overgraded in 15% of cases, 
compared with examination of the whole-gland specimen (35). Bill-Axelson et al. (36) found similar 
data, with 48% of biopsy samples undergraded compared with whole-gland specimen examination. A 
Norwegian study by Kvaale et al. (34) of 1,116 patients showed the same trend for undergrading of 
needle biopsy material. The biopsy-based Gleason score was undergraded (38%) more often than 
overgraded (9%) compared with postoperative examination (34). The Norwegian Radium Hospital 
(NRH) introduced the Gleason score as the standard classification in 2000 (37), and the Gleason score 
with the latest update is currently the standard classification for PCa pathology in Norway. 
1.5. Biomarkers 
1.5.1. PSA 
PSA is a kallikrein-like serine protease (glycoprotein) produced almost exclusively by the epithelial 
cells of the prostate. The function of PSA is liquefaction of the ejaculate, which allows spermatozoa to 
swim freely (38). For practical purposes, PSA is prostate specific but not cancer specific. Thus, serum 
PSA level may also be elevated in the presence of benign prostatic hypertrophy, prostatitis, and other 
nonmalignant conditions. PSA is currently one of the most important biomarkers in oncology and is 
used for screening for and diagnosis and follow-up of PCa. Measurement of serum PSA level is 
considered the most effective test currently available for the early detection of PCa, although the 
effectiveness has been challenged because the positive predictive value of the test is only about 35% 
(6;6;39). The PSA level shows a continuous pattern; that is, the higher the level, the more likely the 
existence of PCa, which means that there is no universally accepted cutoff level for serum PSA that 
excludes PCa (40). 
1.5.2. PSA dynamics (doubling time and velocity) 
PSA doubling time (PSADT) can be used in the posttreatment setting. According to D’Amico et al. 
(41), the PSADT is positively associated with posttreatment PCa-specific survival and is considered a 
surrogate endpoint for PCa-specific survival in men with biochemical recurrence. However, the role of 
the PSADT in predicting tumor biology before treatment is unclear, especially among men with early-
stage PCa (41-43). In some studies, the PSA velocity (rate of change of PSA level) is advocated as a 
predictor of PCa development (44;45), but currently PSA velocity is not a standard form of assessment 
for patients, according to the 2012 EAU guidelines (31) or the 2009 Norwegian guidelines (46). 
1.5.3. Follow-up 
According to the 2012 EAU guidelines (31), regular measurement of PSA level is mandatory in the 
follow-up of patients after curatively intended treatment of PCa. However, the level of PSA used to 
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define treatment failure differs between radical prostatectomy (RP) and radiotherapy (RAD). 
According to international consensus, biochemical PCa recurrence after RP is defined by two 
consecutive measurements of PSA level  0.2 g/L (47). The PSA patterns following RAD are more 
difficult to interpret. A 2006 consensus statement between the American Society for Therapeutic 
Radiology and Oncology (ASTRO) and the Radiation Therapy Oncology Group (RTOG) gave a 
common definition of radiation therapy failure based on PSA level. The definition stated that 
treatment failure with or without hormone therapy is an increase of 2 g/L above the posttreatment 
PSA nadir (the lowest PSA level measured after RAD) (48). This is also known as the Phoenix 
definition (or consensus), after the city where the consensus was reached; this definition is now 
incorporated in both the EAU (31) and Norwegian (46) guidelines. 
1.6. Risk stratification of PCa 
PSA level, Gleason score, and tumor stage are all independent prognostic factors for the outcome of 
PCa (49;50). Using all three variables, D’Amico et al. developed a system of risk stratification that is 
significantly associated with PCa recurrence and PCa-specific mortality (50). The D’Amico 
classification identifies three risk levels and allows for pretreatment grouping of PCa patients: low-risk
patients (stage T1c, T2a and PSA level  10 g/L and Gleason score  6); intermediate-risk patients 
(stage T2b or Gleason score of 7 or PSA level > 10 and  20 g/L), and high-risk patients (any stage  
T2c or PSA level > 20 g/L or Gleason score  8). 
 Optimal treatment of nonmetastatic PCa requires assessment of pretreatment risk categories 
because the treatment recommendations vary accordingly. Slightly modified D’Amico criteria are 
included in today’s treatment guideline recommendations. 
1.7. Treatment modalities 
Local treatment of PCa offers several options. These modalities are active surveillance (AS), RP, and 
conformal external beam radiotherapy (EBRT) (which can be combined with high-dose 
brachytherapy) with or without hormone therapy (31). Another option is to select watchful waiting 
(WW) for a subgroup of patients. The availability of several treatment options gives rise to at least two 
challenges: (1) the provision of adequate information about treatment alternatives to the patient by his 
physician and (2) the risk of suboptimal treatment because of the variations in tumor biology and 
aggressiveness. Therefore, the choice of treatment after the appropriate assessment of tumor extension 
and aggressiveness must be based on individual preferences and on the recommendations of a 
multidisciplinary team of clinicians after consideration of the following factors: 
 TNM classification 
 Gleason score defined by a sufficient number of prostate core biopsies (8) 
 Baseline PSA level 
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 D’Amico risk group 
 Age of the patient 
 Comorbidities, life expectancy, and quality of life (QoL) 
 Expected side effects of therapy 
 Patient’s wishes. 
1.7.1. AS 
According to National Comprehensive Cancer Network (NCCN) guidelines (51), AS (also referred to 
as observation or expectant management) is defined as active monitoring of the course of the disease 
with the intention of intervening with curative treatment if the tumor progresses. AS was introduced 
with the aim of reducing the proportion of overtreatment in patients with clinically confined low-risk 
PCa without relinquishing the opportunity for radical treatment, as was the case with the WW strategy 
(see below). A recently published prospective study (52) offers the most conclusive evidence that AS 
may be the preferred option for most older men with a very low-grade PCa (cT1c, PSA < 0.15 g/L, 
Gleason score  6,  2 core biopsies with cancer, and  50% cancer involvement of any core biopsies). 
An argument against using AS is the need for regular biopsies, which carries a slightly increased risk 
of multiresistant infections in the pelvic area, and the psychological burden related to the patient living 
with an untreated cancer. Except for some types of lymphoma, PCa is the only major cancer type in 
which a group of patients (10–20%) may be candidates for AS rather than for active treatment for 
localized disease; this fact clearly demonstrates the slow progression of low-risk PCa in general. 
1.7.2. WW 
The term WW was coined in the pre-PSA screening era before 1990. Also known as deferred 
treatment, WW refers to the conservative management of PCa until the development of local or 
systemic progression of the disease, at which point the patient would be treated palliatively with either 
transurethral resection of the prostate or other procedures for urinary tract obstruction, and with 
hormones or RAD for the palliation of the metastatic lesions. The rationale of WW is that PCa usually 
progresses slowly and is often diagnosed in older men who have a high incidence of comorbidity and 
competitive mortality risk factors (53). According to the 2012 EAU guidelines (31), WW should be 
considered an option for patients with localized PCa and with a limited life expectancy (i.e., older 
patients with less aggressive PCa and poor health because of comorbidities); WW is not considered a 
curative treatment option. 
1.7.3. Hormone therapy 
The epithelial cells of the prostate gland are dependent on androgens for cellular growth, and depletion 
of androgens will therefore inhibit cell growth in both normal and malignant prostate cells. After 
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surgical castration, only the adrenal glands produce a very low amount of androgens, and therefore 
castration is still considered the gold standard of androgen-deprivation therapy (ADT) against which 
other treatment alternatives are compared. For patients with localized PCa, there are two ways to 
undertake medical ADT: using a luteinizing hormone-releasing hormone (LHRH) agonist, or anti-
androgen therapy. LHRH agonists mimic normal LHRH and occupy the receptors of the pituitary 
gland necessary for normal LHRH signals. The hypogonadal effect (i.e., decreased Follicle-
stimulating hormone (FSH) and Luteinizing hormone (LH) production) decreases the testosterone 
production in the testicles, and the level of testosterone declines by 90–95% to the castration level. 
Anti-androgens are classified as steroidal or nonsteroidal. Steroidal anti-androgens counteract 
androgens and affect secondary sex characteristics. They directly affect gene expression and, because 
of their fat-soluble nature, they are able to diffuse through the plasma membrane’s phospholipid 
bilayer and prevent the intracellular binding of testosterone and dihydrotestosterone to the androgen 
receptor. By contrast, nonsteroidal anti-androgens or “pure” anti-androgens counteract androgens and 
have no steroidal effects. They act by binding to the androgen receptor and preventing the activation 
and subsequent upregulation of androgen-responsive genes by androgenic hormones. There has been a 
trend toward an increasing use of hormone treatment in younger men in the early stages of PCa as 
adjuvant to local treatment. 
 In the Scandinavian Prostate Cancer Group (SPCG)-7 study for high-risk PCa, the addition of 
RAD to endocrine treatment halved the 10-year disease-specific mortality. (54;55). Compared with 
RAD alone for locally advanced or localized high-risk PCa, adjuvant castration-based hormone 
therapy improves clinical outcomes to a significant extent (55-58). In a European Organisation for 
Research and Treatment of Cancer (EORTC) study by Bolla et al., the 10-year clinical disease-free 
survival was 23% for RAD alone compared with 48% in the combined treatment group (56). The 
duration of ADT varies between studies. In the trial by Bolla et al., the patients were treated with ADT 
for 3 years, whereas the patients in the SPCG-7 study were treated with bicalutamide until PCa 
progression or death (55). 
 The necessary duration of ADT treatment is still unclear, but among men with localized PCa 
undergoing conventional-dose radiation therapy, at least 6 months of hormone therapy appears 
necessary to prolong survival among patients with high-risk disease (59). 
1.7.4. RP 
The curative surgical treatment for PCa comprises RP, which involves the removal of the whole 
prostate gland and resection of both seminal vesicles together with sufficient surrounding tissue to 
obtain microscopically tumor-free margins. The 2012 EAU guidelines state that, in men with localized 
PCa and a life expectancy > 10 years, the goal of RP is eradication of disease while preserving urinary 
continence and erectile function whenever possible (60). RP is a recommendable treatment option for 
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selected patients (life expectancy > 10 years) with localized PCa (stage  T2) because RP will remove 
all tumor tissue. For patients in the D’Amico intermediate- and high-risk categories, RP should be 
accompanied by bilateral pelvic lymph node dissection. 
 In a randomized study, SPCG-4, published by  Bill-Axelson et al. (36;61), RP is the only 
treatment for localized PCa with demonstrated PCa-specific survival benefit compared with WW. 
However, the significant survival benefit (40%) was observed only in patients younger than 65 years 
at diagnosis. The SPCG-4 study was undertaken in the 1980s before PSA era, and the patient sample 
of that study is not completely comparable to today’s patient populations. 
 Patients with high-risk PCa (stage  cT2c or Gleason score 8–10 or PSA > 20 g/L) must be 
informed about the likelihood of a multimodal treatment approach. In patients with adverse tumor 
characteristics (positive surgical margins, extracapsular extension, and seminal vesicle invasion), 
adjuvant RAD can often be used after recovery from surgery. A study by Johnstone et al. (62) showed 
that patients (N = 72) who had RP for cT4 disease had survival rates similar to men who received 
RAD plus ADT. Higher rates of cancer-free surgical margins for surgeons with high-volume 
experience suggest that experience is an important predictor of the oncological outcome (63). 
 The two most common procedures for RP are the standard open radical retropubic 
prostatectomy (ORRP) and robot-assisted laparoscopic prostatectomy (RALP). The latter procedure 
uses a specially designed robotic system (da Vinci system ) (64). The first RALP was performed in 
2000 by Binder and Kramer (65), and in Norway the method was introduced at NRH in December 
2004. So far, no significant differences in the oncological outcomes after ORRP versus RALP have 
been reported, but perioperative complications such as blood loss, perioperative blood transfusions, 
and the length of the hospital stay are more favorable for patients having RALP compared with ORRP 
(66-68). In addition, because the procedure by RALP is less traumatic, more patients with comorbidity 
can now be offered radical surgery than in the past. 
 The goal of nerve-sparing surgery is to reduce the risk of postoperative erectile dysfunction. 
The nerve sparing can be graded as none, unilateral, or bilateral (69), although this categorization has 
several weaknesses as a predictor of erectile function and has yielded inconsistent data between 
studies (69;70). Several researchers have suggested recently that nerve sparing is not absolute but 
rather that the neurovascular bundles can sustain varying degrees of damage during surgery (71;72). A 
more detailed definition of nerve sparing has been provided recently by Moskovic et al. (73) (table 
1.2) and Levinson et al. (71). 
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Table 1.2. Nerve-sparing score grading system according to Moskovic et al. (73) 
Criterion Score
Complete preservation 
Near-complete preservation 
Partial resection 
Complete resection  
1 
2 
3 
4 
 In 2009, 1,177 patients were treated with RP for localized/locally advanced PCa in Norway, 
and the RALP technique was used for about 55% of them (personal information from colleague 
Andreas Steinsvik, MD). 
1.7.5. RAD 
Several RAD techniques are applied for the treatment of PCa. According to the 2012 EAU guidelines 
(31), three-dimensional conformal radiotherapy (3D-CRT) is the current gold standard for RAD. Since 
2000, intensity-modulated radiotherapy (IMRT), an optimized form of 3D-CRT, has been introduced 
gradually in leading cancer centers, particularly if the pelvic lymph nodes are to be irradiated together 
with the prostate. Several randomized phase III trials have been conducted in patients with localized 
and locally advanced PCa by the RTOG (United States), the SPCG, and EORTC (74-76). The findings 
have established the total doses and current indications for the combination of external irradiation and 
ADT, as described previously (55;56;77). 
1.7.5.1. Technical aspects of RAD 
There is a well-described dose–response relationship for RAD for the different risk groups of PCa (78-
80), including low-risk groups (81-83), and intermediate- and high-risk groups (57;80;84;85). In daily 
practice, a minimum radiation dose of  74 Gy is recommended (74) for low-risk patients (Gy = Gray, 
the unit for the absorbed radiation dose). 
 Three local techniques are available to escalate the radiation dose with acceptable side effects 
for higher-risk patients: IMRT in combination with image-guided radiotherapy (IGRT), high-dose-rate 
brachytherapy, and proton therapy. IMRT in combination with IGRT might allow dose escalation to 
> 80 Gy with acceptable toxicity (86). IGRT uses a standard CT scan coinstalled with the linear 
accelerator, and gold seeds are implanted in the prostate gland to serve as landmarks for onsite 
positioning of the patient. With precise positioning, margins can be reduced (i.e., on the anterior wall 
of the rectum), which reduces adverse effects (AEs). When one or few pelvic lymph node metastases 
are suspected, several retrospective studies have shown that combination therapy including irradiation 
of the pelvic lymph nodes and ADT improves disease-free interval and overall survival compared with 
ADT alone in this high-risk group of patients (84;87). However, these data have not been confirmed in 
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prospective trials. According to Lawton et al. (88;89), a lower limit of 15% risk of lymph node 
metastases suggests that there should be irradiation to the pelvic field, including the pelvic lymph 
nodes and the prostate (~50 Gy), followed by a boost to the prostate. A nomogram is used to calculate 
pelvic lymph node disease risk (90). 
1.7.5.2. HDR-BT 
HDR-BT (high radiation dose per time unit) is a radiation method in which threadlike radiation 
sources are inserted temporarily into the prostate. The source is introduced through hollow steel 
needles that are inserted through the perineum and into the prostate. Depending on the size of the 
prostate, 12–18 needles are inserted under ultrasound guidance. At NRH, iridium sources (192Ir) are 
inserted through the needles. A high radiation dose ( 10 Gy) is emitted quickly into the core of the 
gland. The advantage of brachytherapy is the limited dose to the surrounding organs, especially the 
anterior wall of the rectum, and thus reduced side effects in this organ. The urethra is another organ at 
high risk of toxicity, and the maximum dose to the urethra should be < 12 Gy. The entire procedure 
takes 2–3 hours and should be repeated after 2 weeks (91), followed by EBRT. 
1.7.5.3. Low-dose-rate brachytherapy (LDR-BT) 
LDR-BT or permanent interstitial brachytherapy is a technique of short-distance radiotherapy using 
low-energy radioactive sources that are placed in or near the tumor in the prostate and that emit 
radiation at a rate of < 2 Gy per hour (92). LDR-BT is recommended as an alternative to surgery for 
men with low-risk localized PCa. The radioactive seeds are implanted permanently into the prostate 
tissue through a transperineal technique guided by ultrasound. In contrast to most European countries, 
LDR-BT is currently not available in Norway. According to the literature, LDR-BT leads to a similar 
biochemical (PSA) recurrence-free survival as RP at 5 years for low-risk patients (93). 
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Figure 1.2. Conformal radiotherapy of PCa 
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1.7.6. RAD after RP 
Patients in whom the surgical prostate specimen show extension through the capsule (pT3) or who 
have malignant cells in the surgical margins may benefit from adjuvant RAD, even in the presence of 
PSA < 0.2 g/L. Salvage RAD is defined as RAD given to a prostatectomized patient with a 
demonstrated local recurrence or increase of PSA level without evidence of metastasis. Three large 
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randomized controlled studies of adjuvant RAD have been published (94-96), and all showed a 
survival benefit with adjuvant RAD or salvage RAD of at least 15% at 5 years in terms of biochemical 
recurrence-free survival. The radiation doses used in these trials ranged from 60 to 64 Gy, which are 
less than the 66 Gy currently recommended for adjuvant and salvage RAD. Thus, as in dose-escalation 
studies of primary radiation for PCa, an increased dose in the salvage setting may improve recurrence-
free survival with acceptable local toxicity; accordingly, doses up to 70 Gy show better biochemical 
recurrence-free survival than lower doses (97;98). Because only one of the patients studied in this 
thesis fulfills the criteria for adjuvant or salvage RAD, and this issue is therefore not discussed further. 
1.8. AEs 
All PCa treatment alternatives except AS and WW have AEs, which affect patients to a variable 
degree. An AE is defined as a harmful and undesired effect resulting from any active medical 
intervention such as surgery, RAD, or medication. AEs are sometimes referred to as iatrogenic 
because they are generated by a treatment initiated by a physician. 
1.8.1. Common AEs after treatment of PCa 
Curative treatment of PCa is frequently associated with several AEs, which can be localized and/or 
general. The most frequent AEs of PCa treatment affect sexual, urinary, and bowel functions (“typical 
AEs”). 
1.8.1.1. Sexual dysfunction 
Sexual dysfunction is the most common AE after curative treatment of PCa  (99). According to the 
2012 EAU guidelines, several studies of men who have satisfactory pretreatment erectile function 
indicate that 29–100% develop erectile dysfunction after surgery because of damage to the 
neurovascular bundle (100-102). 
 In a recently published paper based on the SPCG-4 study with a median follow-up of more 
than 12 years, more men treated with RP reported low intercourse frequency compared with men in 
the WW group (103), although the relative risk was not significant (age-adjusted relative risk 0.69 
(0.47–1.03)). Nerve-sparing surgery had not been used in these men’s operations. 
 Erectile dysfunction may also be caused by RAD because the neurovascular bundle, internal 
pudendal artery, and proximal penile structure are exposed to radiation, leading to eventual 
development of slow tissue destruction, fibrosis, and narrowing of the arterial diameters (104). In 
contrast to the dysfunction that occurs shortly after surgery, the prevalence of erectile dysfunction after 
RAD increases gradually for the first 5 years (105). In a study with few participants (N= 29) who were 
treated between 1986 and 1989, Fransson et al. (106) reported that sexual activity 15 years after RAD 
was very low compared with 34 age-matched controls (38% compared with 78%). 
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 Sexuality is a complex function in which mental state also plays an important role. Studies 
have shown that fatigue and depression, which are common posttreatment AEs, decrease the sexual 
drive. In considering sexual AEs, it is also important to consider the pretreatment situation. For 
instance, both older age (107) and comorbidity (108) negatively affect erectile function. 
1.8.1.2. Urinary dysfunction 
Both RP and RAD affect urinary function but in different ways. Subsequent to RAD, acute 
inflammatory prostatitis and/or cystitis may give rise to symptoms such as increased frequency, 
urgency, incontinence, retention, and dysuria. These symptoms are often transitory, but may be 
followed by long-term AEs such as bladder fibrosis, strictures, sphincter damage, and chronic irritative 
urethritis and/or cystitis. The most common urinary AEs after RAD are increased frequency and 
urgency (109-111). Some studies indicate that HDR-BT results in less urinary dysfunction than EBRT 
(112;113). 
 Patients with localized PCa who had RP tend to experience urinary leakage more often than 
men treated with RAD (114). According to the 2012 EAU guidelines (31), the most common AE after 
surgery is urinary leakage (8%) because of sphincter damage (115). In men undergoing RP, the rates 
of postoperative and late urinary complications are significantly reduced if the procedure is performed 
in a high-volume hospital and by surgeons who perform a large number of such operations 
(100;101;116). The problem in comparing studies is that the definition of leakage varies greatly 
between studies and is categorized most often as the number of pads used daily. 
1.8.1.3. Bowel dysfunction 
Bowel function is affected primarily by RAD because the anterior wall of the rectum is included in the 
radiation field of the prostate. Bowel dysfunction can often be divided into acute and chronic phases. 
Acute AEs are caused by epithelial damage, which may result in diarrhea and painful bowel 
movements. Chronic radiation effects to the rectum include fibrosis and vascular damage, which may 
lead to symptoms such as increased flatulence, rectal bleeding, diarrhea, painful bowel movements, 
rectal urgency, increased frequency, and fecal leakage (117). The symptoms are more severe if the 
lymph nodes also are irradiated, and the risk of late bowel AEs increases with higher radiation doses. 
According Wahlgren et al., HDR-BT causes less severe bowel dysfunction (118). The introduction of 
IGRT has led to reduced doses to the anterior wall of the rectum, and the degree of bowel dysfunction 
is expected to diminish accordingly (119). 
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1.8.2. Other AEs 
1.8.2.1. Fatigue 
Fatigue is a common symptom of cancer and cancer treatment. Fatigue is a multidimensional symptom 
defined by the European Association for Palliative Care as “the subjective feeling of tiredness, 
weakness or lack of energy not improving after rest” (120). If the fatigue lasts for more than 6 months, 
it is referred to as chronic fatigue (CF). The prevalence of CF in the general Norwegian male 
population is about 10% (121), and the prevalence of CF following RP and RAD without ADT in PCa 
patients has been reported as 13–26% (122). The higher rate of CF for RAD compared with surgery 
can be explained by the inflammation-stimulating effect of RAD, which causes the release of 
proinflammatory cytokines that may play a role in the development of CF (123-126). Another 
contributing factor may be that RAD patients often have more comorbidities than RP patients before 
treatment. 
1.8.2.2. Endocrine AEs 
Endocrine effects from adjuvant ADT add to the total load of AEs (127) because long-term use can 
lead to osteoporosis, weight gain, fatigue, depression, and gynecomastia. ADT can also have mental 
effects including depression (128) and impaired vitality (129). A large population-based study in 
Sweden found increased relative risks of nonfatal and fatal cardiovascular disease among all men with 
PCa, especially those treated with ADT (130). According to Poppel et al. (131), long-term use of 
LHRH antagonists is associated with increased risk of diabetes and cardiovascular events. However, a 
recent meta-analysis of randomized trials by Nguyen et al. (132) showed that ADT reduces PCa-
specific mortality and all-cause mortality without increasing the risk of cardiovascular death. 
1.8.2.3. Secondary malignancies 
RAD is linked to the late occurrence of secondary malignancies both in the pelvis and outside the 
targeted area because of low-dose radiation scatter. Secondary malignancies following RAD include 
predominantly bladder cancer, and colon cancer to a lesser extent (133-135). However, secondary 
cancers in general are rare, especially after RAD for PCa, because of the advanced age of most 
patients. The increased risk of secondary malignancies for RAD patients is 0.16% after 10 years (136). 
1.8.3. AEs by treatment modality 
No randomized studies have directly compared the prevalence rate of AEs from RP with those from 
RAD. However, available data indicate a higher risk of erectile dysfunction and urinary incontinence 
following RP and a higher risk of irritative urinary symptoms and bowel dysfunction after RAD (137-
139). For short-term severe AEs, LDR-BT produced significantly less urinary incontinence than RP, 
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but RP caused more urinary irritation than LDR-BT (93). In some studies, HDR-BT was associated 
with fewer rectal AEs and more urinary AEs compared with EBRT (140); however, Joseph et al. (141) 
found no difference between the two treatment modalities. 
Table 1.3. Adverse effects in relation to treatment modalities 
AE RAD RP ADT
Reduced bowel function Moderate    
Reduced urinary function Moderate Moderate   
Reduced erectile function Limited Much Much 
Fatigue Moderate Little Much 
Secondary malignancies Limited   
Mortality 
Diabetes 
Cardiovascular disease 
Mental adverse effect 
  Limited1 
Limited1 
Limited1 
Limited 
1 Nguyen et al. showed no correlation (132). 
1.9. QoL 
A general definition of QoL has been provided by the World Health Organization (1992). 
QoL is defined as an individual’s perception of his position in life in the 
context of the culture and value system in which he lives and in relation to 
his goals, expectations, standards, and concerns. It is broad-ranging concept 
affected in a complex way by the person’s physical health, psychological 
state, level of independence, social relationships, and their relationship to 
salient features of their environment. 
 A more narrow QoL concept concerns health: “Health-related quality of life includes social, 
mental and physical dimensions, and represents the parts of life that are related to the health of an 
individual” (142). In medical studies, QoL is often defined as a multidimensional concept that includes 
a number of physical and mental dimensions. 
 Most importantly, QoL is a subjective assessment that involves the patient’s own perceptions 
of his or her situation, satisfaction, and ability to function in life. QoL is therefore measured by self-
rating using questionnaires, and patients are often asked to rate their symptoms before and after 
treatment, together with eventual AEs. Different instruments have been developed for this purpose. 
The distinction between generic and disease-specific QoL instruments is important. Generic
instruments such as the Short Form-36 (SF-36) and Short Form-12 (SF-12) are not concerned with 
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disease-specific health problems but include various general functions and symptoms. The EORTC 
Quality of Life Questionnaire Core (EORTC QLQ-C30), for example, is applicable to all cancer types 
(143). By contrast, disease-specific instruments include specific features of various diseases. For 
patients with PCa, health-related QoL may be separated into three components: general, cancer 
specific, and disease specific. 
1.9.1. Instruments to measure disease-specific QoL 
Previously, AEs were evaluated only by doctors, but over the past two decades there has been growing 
recognition of the value of incorporating patients’ concerns. Using questionnaires, patients are asked 
to rate their symptoms and functions before and after treatment, together with their AEs. Various 
instruments have been developed for this purpose. Studies of the correspondence between doctors’ and 
patients’ evaluation of AEs after treatment for PCa have shown variable degrees of concordance (144). 
However, a general finding is that doctors in clinical routine work often underreport their patients’ 
AEs and dysfunctions. 
 Several self-rating instruments have been developed to record AEs reported by PCa patients. 
The EORTC Prostate Cancer Module (PR-25) and the University of California at Los Angeles 
(UCLA) Prostate Composite Index (PCI) are examples. The EORTC QLQ-PR25, developed by the 
EORTC Genito-Urinary Tract Cancer Cooperative Group, is a 25-item questionnaire designed for use 
in patients with localized and metastatic PCa. It was developed within the framework of the EORTC 
Quality of Life Group according to rigorous guidelines for module development (145). Published by 
Litwin in 1995, the UCLA-PCI is used widely internationally as a systematic instrument for 
monitoring AEs after treatment for PCa (146). The UCLA-PCI instrument contains 37 items 
addressing five modules. The urinary tract domain is covered by six questions, bowel domain by five, 
sexual domain by nine, somatic morbidity by 14, and demography by three. The psychometric 
characteristics of the UCLA-PCI were developed and tested by Litwin et al. (147). 
 In UCLA-PCI Litwin et al. (146) emphasized that the recording of AEs in PCa patients must 
separate function and bother as two independent domains. Bother can be defined as the degree of 
distress or annoyance caused by any AEs. The distinction between these two concepts is important. 
For example, some men with significant sexual dysfunction are minimally bothered, whereas others 
with only mild dysfunction may feel miserable. Therefore, although function and bother caused by  
erectile dysfunction often are linked together, they represent different domains and must be measured 
separately (148). The responsiveness for change of the UCLA-PCI was documented in the short-term 
recovery period (12 months after treatment) and over the long term (12–24 months) across almost all 
QoL domains. 
 The questionnaire has been developed further with the publication in 2000 of the Expanded 
Prostate Cancer Index Composite (EPIC) with 50 items (149). The assessment of sexual, urinary, and 
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bowel functions and bother as treatment-related AEs is continued in the EPIC-50, although two shorter 
versions of EPIC have been published recently: EPIC-26 with 26 items (150) and EPIC-clinical 
practice (CP) with 16 items (151). EPIC-CP is practical for use in both community and academic 
settings. Due to fewer items the patients complete the EPIC-CP faster, but the reliability and validity 
require further examination. 
1.9.2. New statistical tools to evaluate treatment options 
After a diagnosis of PCa, the patient often wants to know what type of AEs he can expect after 
curative treatment, the expected duration, and the chances of regaining pretreatment function. The 
patient is also interested in knowing whether and to what degree AEs will affect the domains of QoL. 
Several studies have compared and described AEs after the various treatment modalities for PCa 
(137;138;152). Most studies have compared and described these effects in patients treated with either 
surgery (often mixed groups of patients treated with RALP or ORRP) or RAD (often mixed groups 
with or without ADT). 
 Two new statistical methods for prospective assessment of AEs after treatment have been 
introduced recently: proportions of patients regaining a certain percentage of their baseline function 
score (PBS) (113;152) and the generalized estimating equation (GEE).  
 The PBS was first described by Litwin et al. (113), when Malcom et al (152), and the models 
were created based on the occurrence of a patient’s return to baseline score at follow-up time points. A 
patient is considered to have returned to baselineat a time point (for example 6 months) if his domain 
score is at least 90% of his baseline score.  
 The GEE is a method for analyzing associations, with final outcomes adjusted for baseline 
scores and time-dependent covariates (137;138). The GEE is often used to analyze longitudinal and 
other correlated response data, particularly if the responses outcomes are binary. A strength of the 
GEE method is that it is not sensitive to missing data in the analyses. The GEE represents a 
methodological improvement over paired sample t tests and repeated-measures analysis of variance 
because it adjusts for baseline levels and previous times for typical dysfunctions (153). Another 
advantage of the GEE is that if the total number of observations for each individual is random (even if 
these are not independent of the values for the observed responses in that individual) (154). 
1.10. Guidelines 
Guidelines in medicine are developed systematically as professional statements concerning the 
diagnosis, treatment, and aftercare for specific types of diseases. The Institute of Medicine in 
Washington, DC, defines clinical guidelines as “systematically developed statements to assist 
practitioner and patient decisions about appropriate health care for specific clinical circumstances” 
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(155). The recommendations contained in guidelines are based on and summarize the research 
literature and established clinical practice. 
 The use of clinical guidelines has become widespread, and this development is supported by 
professional communities, health authorities, and patients’ organizations in many countries. The aim 
of such guidelines is to assist clinicians in following evidence-based practice in the diagnosis and 
treatment of their patients (156). However, guidelines are not commands or orders, and personal 
treatment decision making in consultation with the patient should not be discarded in favor of 
evidence-based treatment alternatives (157). Deviations from guideline recommendations require 
detailed documentation of the reasons in the patient’s medical record. For most tumor groups, there 
are international (EAU) guidelines (31), American Urological Association (AUA) Prostate Cancer 
Guidelines (158), NCCN Clinical Practice Guidelines in Oncology (51), national guidelines 
(Handlingsprogrammet for prostatakreft (46), Nationälla riktlinjer för prostatacancersjukvård 07 
(159)), and, frequently, local guidelines at major hospitals, such as NRH (DNR retningslinjer for 
prostata kreft 2005). 
 To ensure that guidelines remain useful to clinicians, continuous updating with incorporation 
of new data and new insights is essential. This is a challenge for the authors of guidelines, especially 
national and local hospital guidelines, because they have to be updated continuously according to new 
research findings and developments in clinical practice. According to Shekelle et al. (160), as a 
general rule, guidelines should be reassessed for validity every 3 years. The EAU Prostate Cancer 
Guidelines were first published in 2001, and partial updates were published in 2003, 2005, 2007, 2009 
(full revision), 2010, 2011, and 2012. There have been significant changes since 2001; for example, in 
the 2012 edition, the number of pages increased to 164, from 62 in 2001. Comparison between the 
AUA PCa guidelines and the latest update of the 2012 EAU PCa guidelines shows minor differences 
in their recommendations. 
Table 1.4. Major changes in the 2012 EAU PCa guidelines compared with the 2003 edition 
A chapter about methodology 
A chapter on risk factors 
A chapter about screening and early detection 
More details about diagnoses  
TNM classification from 2009 (minor difference) 
Additional information on watchful waiting, active surveillance, radical prostatectomy, 
radiotherapy, and palliative treatment 
 The guideline concept has been criticized, and some clinicians oppose the application of 
guidelines in their practice (161). Guideline authors are aware of the risk of bias in the 
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recommendations when the highest levels of evidence are lacking. Grol et al. (162) showed that many 
guidelines have been based more on experts’ opinions than on high-level evidence. Accordingly, there 
is a risk that recommendations reflect the view of opinion leaders, the culture at leading treatment 
centers, or the personal interests of the guideline developers rather than evidence-based findings. 
 The recommendation designation in guidelines indicates the strength of a recommendation. 
This requires that guideline authors make judgments about the relative strengths and weaknesses of 
study data, make value judgments about the relative importance of the risks and benefits identified 
according to the evidence, and synthesize conflicting findings from multiple studies. 
 Many guidelines, including the EAU and the Norwegian guidelines produced by government 
health authorities, use the Appraisal of Guidelines for Research and Evaluation (AGREE) (163) 
instrument to provide a framework for assessing the quality of clinical practice guidelines. The 
AGREE instrument comprises 23 key items organized in six domains (Table 1.5). Each domain is 
intended to capture a separate dimension of guideline quality. 
Table 1.5. Structure and content of the AGREE instrument 
Scope and purpose Is concerned with the overall aim of the guideline, the specific clinical 
questions, and the target patient population (items 1–3) 
Stakeholder involvement Focuses on the extent to which the guideline represents the views of its 
intended users (items 4–7) 
Rigor of development Relates to the process used to gather and synthesize the evidence, and 
the methods used to formulate and update the recommendations (items 
8–14) 
Clarity and presentation Deals with the language and format of the guideline (items 15–18) 
Applicability Pertains to the likely organizational, behavioral, and cost implications 
of applying the guideline (items 19–21) 
Editorial independence Is concerned with the independence of the recommendations and 
acknowledgment of possible conflict of interest from the guideline 
development group (items 22–23) 
 
 The levels of evidence (Table 1.6) and grades of recommendation (Table 1.7) provided in 
most guidelines follow the listings because the aim of grading the recommendations is to provide 
transparency between the underlying evidence and the recommendation given. 
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Table 1.6. Levels of evidence 
Level Type of evidence 
1a Evidence obtained from meta-analysis of randomized trials 
1b Evidence obtained from at least one randomized trial 
2a Evidence obtained from one well-designed controlled study without randomization 
2b Evidence obtained from at least one other type of well-designed quasi-experimental 
study 
3 Evidence obtained from well-designed nonexperimental studies, such as comparative 
studies, correlation studies, and case reports 
4 Evidence obtained from expert committee reports or opinions or clinical experience of 
respected authorities 
Modified from University of Oxford, Centre for Evidence-Based Medicine (CEBM) (164) 
Table 1.7. Grades of recommendations 
Grade Nature of recommendations 
A Consistent level 1 studies 
B Consistent level 2 or 3 studies or extrapolations from level 1 studies 
C Level 4 studies or extrapolations from level 2 or 3 studies 
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level 
Modified from University of Oxford, Centre for Evidence-Based Medicine (CEBM) (164) 
 Translating scientific evidence into daily practice is a complex undertaking. Clinical 
guidelines can improve health-care delivery, but there are a number of challenges in guideline 
adoption and implementation. Factors influencing the effective implementation of guidelines remain 
poorly understood. Identifying and understanding the barriers and facilitators are important to the 
development of effective implementation strategies. There is a growing literature that explores the 
barriers to the implementation of clinical guidelines in health care and identifies effective strategies for 
translating research into practice (165;166). Results of studies in the United States and the Netherlands 
(167;168) suggest that about 30–40% of patients do not receive care according to current scientific 
evidence, and about 20–25% of the care provided is not needed or is potentially harmful. 
1.11. Summary 
With the exception of basal cell carcinoma, PCa is the most common cancer among men in the 
developed world. Although the prognosis for PCa is generally favorable, mortality is high and is 
second only to lung cancer in Scandinavian men. The treatment benefit of radical therapy in localized 
PCa is the subject of debate and, until recently, was not documented by randomized trials. For patients 
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with very low-risk PCa, AS instead of immediate therapy seems to be a preferable treatment strategy. 
Several active treatment options are available, however, including different forms of surgery and RAD 
supplemented by hormone therapy for some patients (169). The increasing complexity of treatment 
options has led to an urgent need for generally accepted clinical guidelines. The EAU PCa guidelines 
were first published in 2001, with partial updates in 2003. Given this background, studies examining 
adherence to guidelines are important in assessing the quality of care, especially for cancer centers 
offering patients several treatment modalities. 
 Local therapy for PCa harbors a risk of causing permanent AEs, which may affect the patient’s 
QoL. Therefore, in the late 1990s, several PCa-specific questionnaires were developed and tested 
psychometrically for the prospective measurement of AEs related to therapy. For PCa, the typical AEs 
examined affect urinary, bowel, and sexual function, and the bother related to these functions. New 
statistical tools were introduced. One was to analyze the data on AEs reported after therapy and to 
identify the proportions of patients regaining a certain percentage of their baseline function score at 
later time points (PBS). A second method, the GEE, was developed to analyze the associations 
between treatment related AEs and final outcomes after adjusting for baseline scores and covariates.  
 Given this background, it is important to study further the impact of the psychosocial effects 
of treatment on urinary, bowel, and sexual function, and bother, and to study further the different 
statistical methods that can be used to help patients select the treatment modalities in the context of 
AEs. 
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2. THIS THESIS 
2.1. Background 
During the decade preceding 2004, curative treatment for localized or locally advanced PCa at NRH 
comprised either (1) ORRP or (2) conformal EBRT at a target dose of 70–74 Gy. As devised by the 
D’Amico risk group, RAD was combined with neoadjuvant ADT for 1–3 years’ duration. In 2004, two 
new treatment modalities were introduced in Norway at NRH: (1) RALP and (2) HDR-BT. 
 The availability of several curative therapeutic options and the increase in the number of 
patients triggered a need for treatment guidelines for nonmetastatic PCa at NRH beyond those 
published by the EAU in 2003 (170). Close monitoring of AEs was warranted. In 2004, the UCLA-
PCI questionnaire became available for systematic recording of AEs after PCa treatment. At the 
initiative of NRH physicians and with the permission of Litwin, the UCLA-PCI was translated into 
Norwegian following the published recommendations of Acquadro et al. (142). At the same time, 
previous studies indicated the significance of psychological factors in patients’ perception of AEs 
(171). 
 Against this background, a prospective study that collected relevant data using multiple 
questionnaires was initiated for patients referred to NRH for curatively intended treatment of PCa. 
During the 2004–2007 period, NRH was the referral hospital for the Southern Norway Health Region, 
which covers a population of about 1.6 million people. The study included: 
a. baseline tumor characteristics and demographics 
b. UCLA-PCI measurements 
c. other self-reported instruments: 
i. SF-12 
ii. Hospital Anxiety and Depression Scale (HADS) 
iii. Fatigue Questionnaire (FQ) 
iv. Short Version of the Eysenck Personality Questionnaire (EPQ-18) 
d. follow-up. 
The present thesis was based on this material and the project plan was decided in 2008 to focus on: 
1) adherence to institutional treatment guidelines for localized and locally advanced PCa 
2) the development over time of AEs after curative treatment of PCa. 
2.2. Aims of the studies 
Paper I (172)
Clinicians’ use of guidelines as illustrated by curative treatment of prostate cancer at a 
comprehensive cancer center 
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 To examine and compare the use of different treatment modalities and adherence to the EAU PCa 
guidelines published in 2003 for PCa during period I (December 2004 through December 2005) 
and adherence to the in-house guidelines during period II (2006 through to July 2007). 
 To explore reasons for deviations from the guidelines. 
Hypothesis:
There is high adherence to both the EAU PCa guidelines and institutional guidelines even though 
enthusiasm for new technologies could lead to deviations from the guidelines. 
Paper II (173) 
Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with 
surgery or radiotherapy without hormones 
 To use two models to study the development pattern of AEs after RALP and RAD without ADT 
within 2 years after treatment: the proportions of patients regaining 90% of their baseline function 
score (PBS-90) and the GEE, representing a new type of multivariate analysis. 
 In a prospective design, to examine the causes of sexual, bowel, and urinary dysfunction (typical 
dysfunctions) at 3, 6, 12, and 24 months after either RALP or RAD without ADT and to explore 
intergroup differences. 
Hypotheses:
1) Both PBS-90 and GEE capture clinically relevant aspects of the development of AEs (dysfunctions; 
prediction of dysfunction at 24 months). 
2) Different patterns of typical dysfunctions will emerge after RALP and RAD without ADT with 
clinically important intergroup differences. 
Paper III (174)
Bother problems in prostate cancer patients after curative treatment 
 To explore the posttreatment patterns of bother concerning typical dysfunctions (“typical bother”) 
after RALP, RAD without ADT, and RAD with ADT. 
 To investigate at what posttreatment times the different types of typical bother become stable and 
when significant associations with 24-month bother emerge. 
 To examine the associations between psychosocial variables and typical bother at different times. 
 To explore the relationships between typical bother and typical dysfunctions at various times. 
Hypotheses:
1) Significantly different development patterns of typical bother will emerge from pretreatment until 
the 24-month follow-up after RALP, RAD without ADT, and RAD with ADT. 
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2) At 6 months, the percentages of men with typical bother and the mean levels of bother are 
significantly associated with typical bother at 24 months. 
3) Some psychosocial variables are significantly associated with mean typical bother scores at various 
times. 
4) The correlations between typical dysfunction and corresponding typical bother are high at all time 
points examined. 
2.3. Methods 
2.3.1. Patient recruitment 
From December 2004 to July 2007, patients undergoing curatively intended treatment for localized or 
locally advanced PCa at NRH were invited to take part in a prospective study of treatment-related 
AEs. The inclusion and exclusion criteria are given in Table 2.1. 
Table 2.1. Inclusion and exclusion criteria for patients 
Inclusion criteria 
1. Planned for curative treatment of 
adenocarcinoma of the prostate 
2. Initial cancer diagnosis  24 months before 
treatment 
3. Age < 75 years 
4. No previous invasive cancer 
Exclusion criteria 
1. Other diseases that significantly affect 
intestinal, bladder, or sexual function 
2. Previous WW strategy 
3. Any salvage or adjuvant post-RALP treatment 
for PCa during the time of the survey 
 During the inclusion period, 893 patients were treated for localized or locally advanced PCa at 
NRH; of these, 34 were ineligible. Among the 859 eligible patients, 34 (4%) declined to take part in 
the study, and 538 of the 825 (65%) remaining patients participated. Most of the 287 eligible 
nonparticipating patients (35%) did not receive an invitation to the study for administrative reasons, 
mainly because surgical patients arrived at the hospital in the morning of their day of surgery, leaving 
insufficient time to provide them with information about the study and to collect written informed 
consent (same-day surgery). 
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Figure 2.1. Distribution of patients in the papers in this study 
Eligible patients  
(N = 859)
Declined 
(N = 34) 
 Paper I included all 859 eligible patients, paper II studied the patients treated with RAD 
without ADT and the RALP group (total N = 254), and paper III included the RAD + ADT group 
(total N = 462). In paper II, we reported on 539 recruited patients, versus 538 in paper III. This 
RALP
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RAD
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discrepancy was because, after being included in the study, one patient was found to have a previous 
diagnosis of malignant melanoma and therefore was excluded from the rest of the study. 
2.3.2. Treatment modalities 
The local treatment of recruited patients comprised either surgery or RAD. 
 All prostatectomies were RALP with or without lymphadenectomy. RALP was performed by 
a five-port transperitoneal approach using a three-arm da Vinci system. According to the guidelines, 
during periods I and II, RALP was intended primarily for patients belonging to the low and 
intermediate D’Amico risk groups. Nerve-sparing RALP was performed according to the two 
surgeons’ judgment as to the feasibility in the individual patient. 
 RAD: Patients in the low-risk group were irradiated using a conformal four-field box 
technique (50 Gy to the seminal vesicles and 74 Gy to the prostate) without ADT. From the end of 
2004, the nonsurgical treatment of patients belonging to the intermediate- and high-risk groups 
increasingly included a combination of conformal radiotherapy with HDR-BT as a boost (91). A small 
proportion of patients with N+ disease (one or two lymph nodes) were treated with IMRT (N = 23). 
Patients belonging to the intermediate- and high-risk groups receiving RAD were treated with ADT. 
Intermediate-risk patients received ADT for a total of 1 year, and high-risk patients were treated for 
3 years until the end of 2007 and from then on were given 2 years of treatment. All groups received 
neoadjuvant ADT for 3–6 months. 
 Obturator lymphadenectomy was performed in patients with a PSA level > 10 g/L, T 
category > T2c, or Gleason score > 7. An expert pathologist at NRH reassessed the pretreatment 
prostatic biopsies evaluated at local laboratories to check the Gleason categorizations. 
2.3.3. Periods and adherence to guidelines 
Period I: From the end of 2004 and throughout 2005, a slightly modified version of the 2003 EAU 
guidelines (170) was used at NRH (Table 2.2). The criterion of life expectancy > 10 years left an 
opportunity for individual clinical interpretation; in general, NRH clinicians interpreted this criterion 
as an upper age limit of 70 years for surgical patients and 75 years for RAD patients based on the 
mean life expectancy of 78 years for Norwegian men (13). 
 Period II: In relation to this thesis, period II lasted from 2006 to July 2007. Institutional NRH 
guidelines were formally approved in October 2005, replacing the guidelines used in period I and 
recommending modified treatment strategies for patients with localized or locally advanced PCa. In a 
decision influenced by the publication of the SPCG-4 trial (175), the upper age limit for RALP was 
reduced to 65 years. 
 Throughout the study period, the hospital’s urologists and oncologists met weekly to discuss 
and determine each patient’s treatment based on information from the referral letter, supplementary 
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examinations at the outpatient department, and current guidelines. In 2009 and 2010, the medical 
records of all patients treated during the two periods were reviewed to evaluate whether treatment was 
given according to the current guidelines, as follows.
 Treatment according to guidelines (according group) referred to patients for whom guideline 
recommendations were followed without discussion between the medical specialists.
 Treatment according to guidelines after discussion (discussion group) covered less obvious 
cases for which final treatment according to guidelines was decided after discussion between the 
medical specialists and the patient.
 Treatment deviating from guidelines (deviance group) concerned patients who fulfilled the 
guideline criteria for either prostatectomy or RAD but who did not receive the recommended 
treatment. The surgical deviance group comprised patients who underwent prostatectomy, although 
the guidelines recommended RAD, whereas the RAD deviance group comprised patients who had 
RAD although the guidelines recommended surgery in such cases.
Table 2.2. Criteria of the 2003 EAU Guidelines and NRH Guidelines.  
EAU Guidelines, updated February 2003 NRH Guidelines 2005 
RP1 RAD Discussion RALP RAD Discussion 
  Patient’s wishes   Patient’s 
wishes 
 T2 and 
Gleason  7 and 
PSA < 10 (low) 
and life 
expectancy > 
10 years 
 T3N0 or 
Gleason 8–10 
or PSA > 25 
and life 
expectancy > 
5–10 years 
Small T3A and 
Gleason 5–7 
and low PSA 
(10–25) and life 
expectancy > 
10 years 
 T2 and 
Gleason  7 
and PSA < 10 
and age  65 
years PS 0–1– 
(2) 
T3pN0 or N + 
(IMRT) or 
Gleason 9 or 
10 or PSA < 
70 or age  75 
years, PS 0–1–
2, comorbidity 
rendering 
surgery 
problematic 
Small T3A 
and Gleason 6, 
PSA < 10 or  
T2 or Gleason 
= 8 or PSA 
10–30 or age  
65 years 
1RP was performed as open RP until December 2004, thereafter as RALP. 
2.3.4. Collection of clinical data 
Pretreatment variables (TNM categories [2002], Gleason scores for the prostate biopsies, pretreatment 
PSA levels) were collected from the patients’ medical records at NRH. All patients were allocated to a 
pretreatment risk group according to the method of D’Amico et al. (49). 
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2.3.5. Self-report instruments 
UCLA-PCI
The UCLA-PCI assesses both generic QoL using the SF-12 questionnaire and treatment-related AEs 
of patients treated for PCa (146). AEs are conceptualized according to both function and bother 
(section 1.9.1). The UCLA-PCI comprises six dimensions, which are quantified using Likert scales: 
urinary function (five items), bowel function (four items), and sexual function (eight items). Urinary,
bowel, and sexual bothers (typical bothers) are covered by one item each. As mentioned previously in 
section 2.1, Professor Mark Litwin, MD, who developed the UCLA-PCI, granted us permission to 
create a Norwegian translation according to common procedures for translation and back-translation 
with correction of items. 
 The dimensional scores of the UCLA-PCI were then transformed into scales ranging from 0 to 
100. Higher scores reflect better function and less bother. Previous studies have shown that the 
internal consistency is good, with Cronbach’s alpha coefficients > 0.70 (146). 
Short Form-12 (SF-12) 
The SF-12 is a shortened version of the SF-36 (176) and exhibits the same good psychometric 
characteristics (177). The SF-12 covers two aspects of generic QoL, expressed as the physical 
composite summary (PCS) and mental composite summary (MCS) scores. The original ratings were 
T-transformed so that the mean PCS and MCS scores in the general Norwegian male population were 
set at 50 points, and one standard deviation was set at 10 points (178;179).The SF-12 ratings were 
used in paper III. 
HADS
The HADS was developed to measure symptoms of anxiety and depression in patients with somatic 
diseases (180). The HADS comprises subscales for anxiety and depression, each with seven items, that 
record the anxiety and depression experienced in the past week. The item scores range from 0 (not 
present) to 3 (highly present). The subscale scores thus range from 0 (low) to 21 (high). Caseness of 
depression and anxiety is defined as a score of  8 on each scale. This cutoff point provides the best 
balance between sensitivity and specificity in many studies. There is an extensive international 
literature showing good psychometric properties of the HADS, and the psychometric properties of the 
Norwegian version of the HADS were shown to be excellent in the Nord-Trøndelag Health Study 
(181). The HADS is also documented to work well for cancer patients (182). At baseline, Cronbach’s 
alpha was 0.71 for HADS depression and 0.72 for HADS anxiety. The HADS was used in paper III. 
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FQ
The FQ was developed and validated by Chalder and colleagues in 1993 (183). The FQ comprises 11 
items to measure the level of fatigue experienced by the patient in the past month. The FQ contains 
mental (four items) and physical (seven items) aspects of fatigue, and the ratings are from 0 to 3, with 
higher scores indicating more fatigue. The mental and physical fatigue sum scores range from 0 to 12 
and from 0 to 21, respectively. The total fatigue score is the sum of all 11 items, and the range is 0–33. 
Caseness of CF is defined as the sum of dichotomized scores (0–1 = 0, 2–3 = 1) of  4 and duration of 
6 months or more (184). The psychometric properties of the Norwegian FQ translation are considered 
to be good (121). The FQ was used in paper III; in that sample the Cronbach’s alpha was 0.84 for total 
fatigue. 
EPQ-18
The EPQ comprises three basic personality traits; however, we only assessed neuroticism because it is 
associated with many types of somatic and mental morbidity (185). The answer “yes” was scored as 1 
and “no” as 0, giving a neuroticism score range of 0 to 6 (186), which is interpreted as being very 
nervous (high score) to feeling very safe (low score) (187). At baseline, Cronbach’s alpha 0.64 was for 
neuroticism. Neuroticism was included in paper III. 
2.3.6 Statistical considerations 
All papers 
Continuous variables were analyzed with t tests, and categorical variables with Pearson’s chi-square 
test. Nonparametric tests were used in cases of skewed distributions. All analyses were performed on 
SPSS, version 15, or PASW for PC, versions 17 and 18. 
Paper I 
Continuous variables are described as median and range, and categorical variables as proportions. The 
level of significances was set at p <0.05 and all tests were two sided. 
Paper II 
Descriptive statistics included the mean and standard deviation (SD) for continuous variables. The 
level of significance was set to p 0.01 because of multiple comparisons, and all tests were two sided. 
At each time point, the mean functional scores of the two therapeutic groups were compared using 
linear regression analyses adjusted for confounders (D’Amico risk group, age, and education). 
 Within each of the two therapeutic groups, factors associated with typical dysfunctions were 
analyzed using the GEE technique and the PBS statistics. In the GEE method, associations between 
independent variables (treatment modality, age, level of education, D’Amico risk group, and function 
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scores at various times) were analyzed with the function at 24 months as the dependent outcome. The 
strengths of the associations are expressed as beta coefficients with 95% confidence intervals. Wald 
statistics were included to show if the predictors made a significant contribution to the prediction of 
outcome if the value was different from zero. 
 In the PBS-90, as used by Malcolm et al. (152), we calculated the proportion of patients who 
reached 90% of their pretreatment function scores at the different posttreatment times and evaluated 
when this proportion did not differ from the situation at 24 months. The PBS-90 percentages were 
dichotomized according to whether the patients did or did not achieve 90% of the baseline or better 
function. Patients with a pretreatment function score < 30 were excluded from the analyses because 
they could have a high PBS-90 with a low absolute score. No patients were excluded because of low 
urinary function (score < 30), one was excluded because of low bowel function, and 40 (16%) were 
excluded because of low sexual function. As described by Malcolm et al. (152), the changes in PBS-
90 with time were examined using chi-square tests or Fisher’s exact tests if there were < 25 patients in 
one of the groups. We used Kaplan–Meier curves to analyze the proportions of patients whose 
function scores returned to PBS-90. 
Paper III 
Descriptive statistics in paper III include the mean and SD for continuous variables and proportions 
for categorical variables. The GEE was used to identify factors associated with the bother level at 24 
months. Independent variables were D’Amico risk group, age, and educational level at baseline, and 
anxiety, depression, neuroticism, total fatigue, and PCS-12 and MCS-12 at each time. The strength of 
the associations is expressed as beta coefficients with 95% confidence intervals. As in paper II, Wald 
statistics were used. We used repeated measurement (ANOVA) to analyze the change in the bother 
score with time within each of the three treatment groups because there were no missing values. At 
each follow-up time, typical bother was reported as both continuous and categorical variables. In 
contrast to the interpretation of means, which were used in similar research papers, categorical 
findings are easy to explain to individual patients. 
 Similarly to paper II, in paper III, we calculated the percentages of patients who had returned 
to their baseline bother score (PBS-100) at each time point. Because of the scoring steps of the single 
bother items, we chose “return to 100% of the baseline score” as the outcome. For the same reason, 
and in contrast to the procedure followed by Malcolm et al. (152) and by us in paper II, we did not 
exclude any patients. Bother stability was defined as the time when the percentages of patients who 
had recovered to 100% of the baseline bother score did not differ significantly from those at 24 
months. 
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 To analyze the relationship between bother and function, we used Spearman’s correlation 
coefficients with the following classification: low < ±0.3, medium ±0.31 to ±0.49, and large  ±0.50 
(188). 
 The crude and adjusted associations between treatment modalities as independent variables 
and bother dichotomized as present or absent (reference) at all time points were analyzed using 
univariate and multivariate logistic regression analyses. We adjusted for D’Amico risk groups (49), 
age, and educational level at baseline; and anxiety, depression, neuroticism, total fatigue, PCS-12, and 
MCS-12 at every time point. The strength of each association is expressed as an odds ratio (OR) and 
95% confidence interval. 
 The level of significance was set to p<0.01 because of the inclusion of multiple comparisons, 
and all tests were two sided. We also report some interesting results that show only a trend toward 
significance (p=0.01). 
3. ETHICAL CONSIDERATIONS 
All participants provided written informed consent to participate, including permission for the retrieval 
of relevant data from their medical records. The study was approved by the Regional Committee for 
Medical Research Ethics of Southern Norway and by the Norwegian Data Inspectorate. 
4. RESULTS 
4.1. Paper I 
A total of 859 patients were included in this study: 315 (37%) patients during period I (end of 2004 
and throughout 2005) and 544 (63%) during period II (2006 to mid-2007). Most PCa patients (N = 
713, 83%) were treated according to current EAU and in-house guidelines;  569 patients (66%), 144 
patients (17%), and 146 patients (17%) were allocated to the according, discussion, and deviance 
groups, respectively. 
 Of the 146 patients in the deviance group, 119 men (82%) had surgery (RALP), and the other 
27 patients received RAD instead of RALP. The distributions in the deviance group were 12% (N = 
37) in period I (end of 2004 to 2005) and 20% (N = 109) in period II (2006 to mid-2007). The size of 
the surgical group increased by more than a factor of two, from N = 111 in period I to N = 250 in 
period II. By contrast, the number of irradiated patients decreased from 10% to 2% from period I to 
period II in the deviance group. The reasons for the deviation in period II were age >65 years (N = 70) 
and surgery in patients with T3 tumors (N = 10), Gleason score >8 (N = 13), and combinations (N = 
26). According to the medical records, 87 men (73%) in the surgical deviance group chose their 
treatment based on information received from the referring physician and/or the urologists at NRH. 
 
44
Deviance from guidelines in the RAD group (N = 27) occurred because of the patients’ expectations 
about preserving sexuality and/or fertility. Comorbidity was the reason for RAD in five of the patients. 
4.2. Paper II 
A total of 254 PCa patients participated in this study; 150 patients were treated with RALP and 104 
patients with RAD without ADT. 
 Within 6 months after treatment with RALP or RAD without ADT, the percentage of men 
who recovered to 90% of their baseline urinary and sexual functions stabilized. The percentage of 
patients who had recovered at this time did not differ from that observed at 24 months. The similar 
percentages of men who recovered bowel function had stabilized at 3 months for both treatment 
modalities. The GEE showed that the scores for urinary, sexual, and bowel functions at 6 and 12 
months were associated significantly with the function scores at 24 months. Age at baseline was 
predictive for sexual and bowel dysfunction at the 24-month follow-up. 
 These results show that the GEE is an acceptable method for predicting dysfunction at 24 
months and that the PBS-90 informs the patient of the time at which his dysfunctions will become 
stable. Therefore, both the PBS-90 and GEE have merits and supplement each other in the context of 
outcome assessment. 
 RALP patients experienced a significant reduction in sexual function 24 months after 
treatment. At all posttreatment times, the mean sexual function scores were significantly lower in 
patients treated with RALP than in those treated with RAD without ADT. RALP patients also showed 
a reduction in urinary function, whereas only slight impairment of urinary function was reported by 
patients treated with RAD without ADT. For bowel function, the reduction was limited to the RAD 
without ADT group; significantly better bowel function was reported at all times after RALP 
compared with after treatment with RAD without ADT. 
4.3. Paper III 
Each of the three primary therapies for PCa—RALP, RAD, and RAD with ADT—produced 
characteristic patterns of changes in urinary, sexual, and bowel bother during the first 2 years after 
treatment. Sexual (70%) and urinary bother (40%) were the most frequent concerns in RALP patients, 
whereas bowel bother (41%) was most common among irradiated patients. 
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Figure 4.1. Mean scores of bother at various times and findings of repeated-measures ANOVA 
at baseline and after 3, 6, 12, and 24 months of follow-up in patients treated with RALP, RAD, 
and RAD with ADT (identical to Figure 2 in paper II) 
Sexual bother, p-values 
RALP baseline vs 3, 6, 12, and 24 months 
(p<0.001) 
3 vs 24 months (p<0.001) 
6 vs 24 months (p=0.002) 
RAD no significant difference (p=0.09) 
RAD+ADT baseline vs 3, 6, 12, 24 months 
(p<0.001) 
Urinary bother, p-values 
RALP baseline vs 3 vs 6 vs 12 months (p<0.001) 
baseline vs 24 months (p= 0.002) 
RAD no significant differences (p=0.50) 
RAD+ADT baseline vs 3 vs 6 vs 12 months 
(p<0.001) 
baseline vs 24 months (p=0.002) 
3 vs 24 months (p<0.001) 
6 vs 24 months (p=0.002) 
Bowel bother, p-values 
RALP no significant difference (p=0.14) 
RAD baseline vs 3, 6, 12, and 24 months 
(p<0.001) 
RAD+ADT baseline vs 3, 6, 12, and 24 months 
(p<0.001) 
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 The PBS-100 showed that by 3 months for some bother variables and within 6 months after 
treatment for all variables, the percentages of men with all typical bother variables had stabilized and 
did not differ significantly from the baseline levels at 24 months (Figure 4.1). 
 The GEE showed that the demographic and psychosocial variables at baseline, except for high 
neuroticism, had hardly any influence on any of the three bother domains. There was a trend toward 
significance (p=0.01) for urinary bother at 24 months. Sexual bother at 24 months was significantly 
positively associated with sexual bother at 3 (p=0.001), 6 (p<0.001), and 12 months (p<0.001). Higher 
urinary bother at 6 (p=<0.001) and 12 months (p=0.002) was significantly associated with higher 
urinary bother at 24 months. Bowel bother at 12 months (p=0.006) was significantly associated with 
bowel bother at 24 months, whereas bother at 6 months showed a trend toward significance (p=0.01). 
 The risks of sexual and urinary bother were significantly lower in irradiated patients than in 
those treated with RALP. The risk of bowel bother increased in the irradiated patients, although it 
reached significance only for the RAD group at 6 and 12 months (p=0.002 and p=0.006, respectively). 
Multivariate analyses showed that high neuroticism at baseline was significantly associated with high 
sexual bother at 3 months (OR 1.26, p=0.007) and with high urinary bother at 24 months (OR 1.40, 
p=0.007). At baseline, reduced physical QoL (PCS-12) was significantly associated with sexual bother 
at baseline (OR 0.95, p=0.003). Reduced physical QoL at 3 months was associated with bowel bother 
at the same time point (OR 0.88, p<0.001), and reduced physical QoL at 24 months was associated 
with urinary bother at the same time point (OR 0.85, p<0.001). 
 Our findings show a strong relationship between function and bother scores for the urinary and 
bowel domains (Spearman correlation coefficient  ±0.50) and contrast with the findings related to 
sexuality. 
5. DISCUSSION 
5.1. Methodological considerations 
5.1.1. Cross-sectional and longitudinal studies 
To satisfy the objectives of paper I within each of the two periods of the cross-sectional study, we 
aimed to assess adherence to institutional treatment guidelines for curatively intended treatment of 
PCa in 859 patients. By comparing the results from the two periods, we were able to assess eventual 
time-dependent changes, thus adding a “longitudinal” aspect to our results. Information collected at 
one time point gives only a “snapshot” of the situation. Cross-sectional studies are suitable for 
assessing prevalence rates and detecting associations between variables (189). A cross-sectional study 
design does not provide information about causality, but the results of cross-sectional studies are 
suitable as a basis for administrative or political initiatives and decisions, and for making hypotheses 
about causality to be tested in studies with a more rigorous design. 
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 In papers II and III, we assessed AEs after different treatments for localized and locally 
advanced PCa at different times up to 2 years and compared these with the pretreatment status. These 
are prospective longitudinal studies because the information was obtained from the same individuals at 
more than one time point (189). Because a specific exposure occurs before the development of a 
disease or AEs, longitudinal studies may help elucidate the associations between exposure and a health 
outcome, and may help identify the predictors of AEs after treatment (190). 
5.1.2. Bias 
Bias can be defined as systematic error arising from the design or conduct of a study. This systematic 
error results from flaws in either the selection of study participants or the procedures for gathering 
relevant information about exposure and/or disease. The observed study results tend to differ from the 
true results in the reference population; this tendency toward erroneous results is called bias. A 
systematic error (bias) should be distinguished from a sampling error because of random variability, 
which results from the use of a study sample to estimate the study parameters in a reference 
population. The sample estimates may differ substantially from the true parameters because of random 
error, especially if the number of individuals included is small. 
5.1.2.1 Selection bias 
A selection bias is operating if the selected patients and controls differ systematically from their 
respective populations. This thesis included only patients treated at NRH, and we cannot exclude the 
possibility that these patients differ from patients treated curatively at other Norwegian hospitals, for 
example because of sociodemographic variables such as a higher level of education. In papers II and 
III, a relatively large percentage of eligible patients were not invited to participate. The main reason 
was lack of time for surgical patients who arrived at NRH in the morning of their day of operation 
(same-day surgery). To determine whether there was a selection bias for the recruited patients, we 
performed attrition analyses for papers II and III. The Gleason score, T category, and PSA level at 
baseline did not differ significantly between participants and nonparticipants. The same analysis was 
performed on those who withdrew or who delivered incomplete data, and we found no significant 
differences between participants and nonparticipants for the above-mentioned variables. However, we 
cannot rule out the possibility that those who withdrew from the study or were lost to follow-up had 
more dysfunction, were more bothered, or suffered more from psychosocial problems after treatment 
than the participating patients. Thus, we cannot exclude the possibility that nonparticipants and 
participants differed systematically on the outcome measures. 
5.1.2.2 Confounding factors 
Confounding factors are variables in statistical models that correlate (positively or negatively) with 
both the dependent variable and the independent variable. In papers II and III, an important aspect of 
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the statistical analyses is that we adjusted for possible known confounders. In paper II, RALP and 
RAD without ADT were compared. Because of the guidelines, there were some differences in 
pretreatment tumor characteristics between the two treatment groups; that is, RALP patients were 
significantly younger, were more frequently employed, and were better educated compared with RAD 
patients. RALP patients also had lower D’Amico risk group scores than RAD patients. 
 Confounding factors such as the levels of specific variables at baseline at other times in the 
study are adjusted for in GEE analysis. Nevertheless, there are some limitations to this strategy. The 
GEE statistical tool includes concurrent adjustment for other associated and possible confounding 
variables and therefore the association between the independent variables of interest and the outcome 
is analyzed with a minimum of error from the confounding factors. As a rule, there should be at least 
10–15 events for each covariate included in a regression model. Avoidance of a type II statistical error 
(not detecting existing differences) thus required a sufficient number of patients, which was the case in 
paper II and paper III (RAD, N = 104; RALP, N = 150). 
 In papers II and III, the GEE method adjusted for confounders assessed before treatment and 
during the follow-up. In paper III, analysis of the 24-month outcomes identified D’Amico risk group, 
age, educational level, anxiety, depression, neuroticism, total fatigue, PCS-12, and MCS-12 as 
potential confounders. In all three papers, the baseline tumor characteristics and sociodemographic and 
psychosocial factors differed between the three treatment groups. We used multivariate analyses to 
adjust for sexual, urinary, and bowel bother at baseline and at later times, and to eliminate the effects 
of confounding factors. However, not all potential confounders, such as civil status and somatic 
comorbidity, were included in the model in paper III. 
5.1.2.3 Information bias 
Information bias has two meanings. First, it can refer to the presence of incorrect information 
regarding the status of the sampled individuals versus the status of the controls. We do not consider 
this type of bias to be relevant to this thesis. Second, information bias may refer to systematic 
deviations of key information or responses to the questionnaires completed by the participants. To 
minimize the risk of information bias related to cancer-related variables, the medical records were 
examined several times. However, we cannot rule out the possibility that patients entered the 
“socially” correct answers rather than more personally correct answers for some questions, particularly 
those relating to sexual function and bother. During the work on this thesis, it became evident that the 
registration of nerve-sparing procedures was not accurate. This is reflected in the two different ways 
that the nerve-sparing procedures were reported (paper II versus III), and is a source of information 
bias. 
 Interpretation bias is a type of information bias that is operating if patients or interviewers, 
deliberately or inadvertently, interpret questions or information systematically in a way not intended. 
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For questionnaires, halo effects are well-known phenomena among responders, but we had no check 
for these through parallel interviews (191). However, our conclusion is that we do not consider 
interpretation bias to be a major operating factor in this thesis, especially because we used established 
and validated questionnaires to obtain valid and reliable information on the outcome measures. 
5.1.2.4 Recall bias 
Recall bias is operating if the patients, deliberately or inadvertently, systematically distort their 
responses regarding previous events because of memory problems or suppression. In the prospective 
studies, we asked mainly for current AEs and symptoms, and only a few retrospective demographic 
and clinical data were assessed. We have no reason to believe that these data were a source of recall 
bias. 
5.1.3. Internal and external validity 
Internal validity reflects whether the effects we found can be related to the causes that we consider, 
namely the use of guidelines (paper I) or the treatment modalities for PCa applied (paper II). For 
example, the relative absence of bowel bother after RALP or of urinary bother is expected, based on 
daily clinical experience, thus validating our patients’ responses. We have no reason to believe that 
these results could have occurred because of other factors not examined. 
 External validity refers to the extent to which the study results can be generalized to the whole 
group of PCa patients receiving curatively intended treatment. To consider the internal validity, 
representativeness, possible bias, and confounding factors must be evaluated because they all may 
affect internal validity (190). 
 Papers II and III included patients who received RALP, RAD without ADT, or RAD with 
ADT. As noted above, many surgical patients were not invited to participate. We cannot exclude the 
possibility that the nonrecruited patients differed from those who participated. However, we performed 
an attrition analysis to compare the nonresponders and responders at baseline, and we found no 
significant differences in age, marital status, Gleason score, T category, PSA level, or D’Amico risk 
group. Therefore, we consider the internal validity of the results of the study of curatively treated PCa 
to be satisfactory. 
 Paper I showed that most treatments were performed according to local and EAU guidelines, 
and these treatments were considered the standard treatments for PCa in several European countries 
during the study’s timeframe. The external validity of our results is supported by the consistency of 
our results with those of other study groups. Further confirmation requires replication of our study at 
similar university hospitals with similar available technologies. 
 When assessing external validity, the clinical T category must be considered a confounding 
factor. Intuitively, larger tumors would require more extensive treatment (more extended operations, 
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larger target fields) and could therefore affect outcome (i.e., AEs from treatment). A higher percentage 
of patients with T3 tumors were operated on in our study compared with other recent publications 
(137;138). By contrast, a higher percentage of patients with advanced primary tumors (T3) were 
offered prostatectomy, as documented in other recent studies (192-194). 
5.2. Discussion of the main findings 
5.2.1 Paper I 
Guidelines are developed to benefit patients by defining current standard management, but they may 
not function as intended if they are incorrect or are misinterpreted (195). Paper I addressed these 
concerns. 
 Of all PCa patients receiving curatively intended treatment at NRH during the study period, 
17% were not treated according to current guidelines. This is slightly less than or equal to the values in 
the study by Grol et al. (196). These authors analyzed > 70 evidence-based guidelines for family 
medicine in the Netherlands and found that recommendations were followed in 67% of the decisions, 
although there were large variations between physicians and between guidelines (196). In our study, 
the main reason for not being treated according to the guidelines was the age limit of 65 years for 
RALP, which was applied during the second data-collection period. This age limit contrasts with the 
2003 EAU recommendations and raises the question of whether such a strict age limit should be stated 
in the guidelines. The results of the SPCG-4 trial were the basis for this age limitation in the NRH 
guidelines. In this trial, prostatectomy did not improve survival in patients aged  65 years compared 
with controls (175). However, this was the result of a subgroup analysis. Although the experiences 
from the SPCG-4 should not be discarded, the trial’s patients were not entirely comparable to today’s 
patients with nonmetastatic PCa, because the PSA test and RALP were introduced after that trial was 
conducted. In addition, life expectancy is significantly higher today than it was 20–25 years ago, 
mainly because of reduced mortality from cardiovascular diseases. Retrospectively, it is evident that 
the 65-year age cutoff has never been applied strictly during the day-to-day decision-making process 
between urologists, oncologists, and patients at NRH. 
 After obtaining experience with the new robot platform, the surgeons felt confident to perform 
RALP in patients with T3 tumors. This explains why an increasing percentage of patients with T3 
tumors were operated on and did not receive primary RAD, as recommended in the guidelines from 
period II. In agreement with this practice, a recent study suggested that patients with a high Gleason 
score of 8–10 may benefit from a prostatectomy, which can provide durable local control and 
favorable cancer-specific survival (197). We should not forget that most patients in this group selected 
surgery after consideration and discussion with their referring urologist or hospital urologist. However, 
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the medical records do not reveal whether and to what degree the patient had the opportunity to 
discuss treatment alternatives with an oncologist. 
 In the SPCG-7 trial, in high-risk patients, RAD combined with hormones proved to be more 
beneficial up to age 75 years compared with hormones alone (55). Data for this age group and risk 
category are not available for surgically treated patients. For patients in the deviance group who chose 
RAD, the most frequent reason was to maintain sexual function. The differences between AEs after 
surgery and RAD shown in papers II and III support this consideration. 
 Our principal view is that institutional guidelines for a disease such as PCa with several 
treatment modalities available are important to ensure the quality of clinical care. Guideline-based 
medical practice must employ two strategies. First, deviance from guidelines should be documented in 
the patient’s medical record. Second, regular monitoring of compliance with guidelines, updating of 
the scientific knowledge, and appropriate guideline revisions are needed. These two strategies will 
help avoid errors and ensure that the most recent knowledge is applied in the daily clinical 
management of patients. 
 In addition to providing support for patients and physicians, guidelines can be viewed as tools 
to help policy makers and health bureaucracies provide more consistent and cost-effective medical 
care. Important conclusions from our study are that guidelines should not be too strict and that they 
should allow individual well-reasoned deviations, provided such deviations are documented in the 
medical records. Finally, to justify any deviations from guidelines, clinicians should be aware of the 
level of evidence underlying the major recommendations in the guidelines. 
 Although the single-institution design of paper I might be viewed as a limitation, we believe 
that similar institutions experience similar guideline deviations and must also regularly and frequently 
analyze compliance with guidelines. 
5.2.2 Paper II 
The PBS-90 showed that, by 6 months after treatment, urinary function in patients treated with RALP 
and sexual function in patients treated with RAD without ADT had stabilized. For bowel function, 
3 months elapsed before stabilization. GEE analyses showed that age at baseline was predictive for 
sexual dysfunction at the 24-month follow-up. At 6 and 12 months, urinary, bowel, and sexual 
function were significantly associated with their corresponding 24-month function. Patients treated 
with RALP had a significant and enduring reduction of sexual and urinary function 24 months after 
treatment compared with those treated with RAD without ADT. For bowel function, the reduction was 
smaller for both groups, and patients treated with RALP had significantly better bowel function at all 
time points. 
 These findings support previous studies showing that RALP and RAD without ADT produce 
different patterns of AEs (113;137;138;147;152). Our findings are consistent with those of Pardo et al. 
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(138), although they had a longer follow-up period (36 months) and studied open RP and as well as 
RALP. Pardo et al. found that RP regularly caused urinary incontinence and sexual dysfunction, 
whereas RAD and brachytherapy caused some sexual dysfunction. RAD also caused bowel AEs. We 
note that Pardo et al. (138) used the EPIC-50 questionnaire, which is a further development of the 
UCLA-PCI (see section 2.3.5). Our findings are also consistent with those of studies that included 
patients on hormonal treatment; for example, Litwin et al. (113) and Sanda et al. (137) found that 
urinary control and sexual function were better after RAD compared with RP and that RAD caused 
more bowel dysfunction. 
 We found significantly poorer posttreatment erectile function in our surgical patients 
compared with those of Pardo et al. (138), Malcolm et al. (152), Sanda et al. (137), and Litwin et al. 
(113). One possible explanation is that Litwin et al. (113),  Sanda et al. (137), and Pardo et al. (138) 
studied only patients in clinical T1/T2 categories. In the sample of Malcolm et al. (152), more than 
80% of the patients had cancer at less than the T2a stage. By contrast, our sample comprised RALP 
patients only, and a considerable proportion of the patients were at more advanced clinical T stages 
(26% > T2b). To offer RALP to such high-risk patients reflects common clinical practice in many 
university hospitals (192-194), but increases the risk of postoperative erectile dysfunction because of 
the reduced opportunity for nerve-sparing surgery. 
 Sexual function was significantly better at baseline among RALP patients compared with 
irradiated patients, which was expected because the operated patients were significantly younger than 
the patients treated with RAD without ADT. 
 As noted in paper II, one limitation of our study is that the two treatment groups differed 
significantly at baseline (Table 1 in paper II). RALP patients were younger and there was a larger 
proportion of D’Amico low-risk patients in those treated with RALP than in those treated with RAD 
without ADT. Previous studies show that age and stage of PCa are important determinants of AEs 
(113). Despite this limitation, our results can help inform patients about the types of side effects to 
expect after various treatment modalities. 
 In paper II, we used both GEE and PBS-90 to examine the development of typical 
dysfunctions in PCa patients treated with either RALP or RAD without ADT. As mentioned earlier, 
one strength of the GEE method is the simultaneous inclusion of pre- and posttreatment variables in 
the same multivariate analysis. In contrast to GEE, PBS-90 is a univariate analysis that calculates the 
percentage of patients who return to 90% of baseline function. The results produced by PBS-90 may 
be easier for patients to understand than those from GEE. To our knowledge, no previous studies have 
combined GEE and PBS-90 in the same prospective outcome study to maximize outcome prediction 
and to determine the time to stability of typical dysfunctions. No previous study has compared typical 
dysfunction after RALP or RAD without ADT. In the study by Pardo et al. (138), surgery was 
performed by radical retropubic prostatectomy. 
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 In many studies, posttreatment AEs are rated by physicians (198;199). Patients with PCa often 
report more frequent and more severe AEs than their physicians (200;201). These findings indicate the 
risk that physicians generally underestimate the burden of posttreatment AEs in their PCa patients. 
Therefore, as in our study, patient-reported observations are an important supplement to physicians’ 
reports (146;202;203). 
 When planning our study, the UCLA-PCI questionnaire was selected as a compromise 
between the interests of oncologists and urologists, for whom the strategy of self-reported AEs was a 
new methodology in 2004. A weakness of the UCLA-PCI questions is that irritative symptoms are 
poorly covered in contrast to the more recently developed EPIC-50 (149). These symptoms are 
relatively common after RAD treatment (99;137) and are important especially for the interpretation of 
AEs in RAD patients. 
 The strength of our study compared with previous studies (113;137;152;201) is the 
homogeneity of our treatment groups. Most other studies of typical dysfunctions are based on mixed 
samples that included patients treated both with and without neoadjuvant ADT and did not consider 
post-RP RAD. ADT may confound the effects of RP and RAD on typical dysfunctions, particularly 
sexual dysfunction (137). However, a considerable proportion of patients with PCa are treated with RP 
or EBRT without hormones. To our knowledge, the current study (paper II) and the study by Pardo et 
al. (138) are the only two studies of AEs in patients treated with RAD without ADT. 
 In our study, posttreatment dysfunction rather than oncological results represented the 
principal outcome, and we followed the patients for 24 months. The post-RP AEs occur shortly after 
the operation, with some recovery during the 24 months, whereas radiation may induce AEs that may 
develop or worsen during subsequent years. Therefore, a follow-up longer than 24 months would be of 
interest, especially if long-term AEs are influenced by the oncological outcome. However, according 
to the literature, function related to RAD shows only minor changes beyond 24 months after therapy 
(138;204). 
 The patients who participated in the surgery group were operated on by the two in-house 
surgeons with RALP competence. Nevertheless, the definition of nerve-sparing RP in paper II differed 
from that used in paper III. In the interval between the writing of these two papers and with the 
agreement of the operating surgeons, an independent evaluator reexamined the operation records 
concerning the performance of nerve-sparing procedures. Unexplainable discrepancies and 
inconsistencies were observed, and we can make no firm conclusions about the influence of the nerve-
sparing procedure on sexual function in papers II and III. 
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5.2.3 Paper III 
In contrast to paper II, which used posttreatment dysfunction as the main outcome, paper III examined 
posttreatment bother. A third group of patients who had RAD combined with neoadjuvant ADT was 
added. 
 Sexual and urinary bother represented the most frequent concerns after RALP, whereas bowel 
bother was reported most often by patients treated with RAD with or without ADT. The GEE showed 
that the bother scores at 3 and 6 months were significantly associated with the bother scores at 24 
months for all treatment groups. By 3 months for some bother variables and within 6 months after 
treatment for all variables, the percentages of men with all typical bother variables had stabilized and 
did not differ significantly from the baseline levels at 24 months. Function and bother for the urinary 
and bowel domains showed strong correlations, but not in the sexual domain. The associations 
between psychosocial factors and any typical bother were weak. 
 The finding that RALP patients had considerable sexual bother after treatment is consistent 
with findings from previous studies (113;152;205). Our study showed slightly more typical bother 
than reported in previous studies (113;137). One possible explanation is that our sample included more 
patients with high clinical T categories. As noted in the 2012 EAU guidelines (31), it is important to 
inform patients in a high T category that they may experience several types of bother after surgery to 
avoid unrealistic expectations about posttreatment function. 
 As observed in other studies, we also found that the differences in mean levels of sexual 
bother between operated and irradiated patients declined over time (205-207). By contrast, the small 
differences in mean bowel bother scores were consistent over time. Bowel bother showed no 
significant improvement after 12 months for any of the RAD groups, a finding that is also consistent 
with that of previous studies (117;208). As discussed in paper III, the reduction in sexual bother over 
time for all three modalities may be explained at least partly by a response shift and may not reflect an 
improvement in function only. Sprangers and Schwartz argue that patients confronted with a life-
threatening malignancy adapt to this challenge by changing their internal standards and values (209). 
The reason the same response shift does not occur for bowel bother may be that the symptoms, such as 
rectal bleeding and rectal incontinence (117), are more insidious and more socially incapacitating. 
Another explanation may be that, although bowel dysfunction occurs frequently after RAD, it is of 
minor concern to most irradiated patients and does not elicit any response shift reaction. It would be 
difficult to prove statistically that there is any significant reduction of the limited degree of bowel 
bother observed. 
 Surprisingly, we found few significant associations between bother and psychosocial variables 
at baseline. Other authors (205;210-212) have reported such associations, although they also found 
them to be weak. The patient’s personality traits (e.g., neuroticism) can influence the perception and 
reporting of posttreatment bother; this is discussed by Block et al. (210). 
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 As in a previous study by Litwin et al. (147), we observed strong correlations between urinary 
and bowel functions and bother within the individual patient. Unlike Litwin et al. (147), we did not 
find the same correlations between sexual bother and function. However, in a subsequent paper, 
Litwin et al. (206) stated that sexual function and sexual bother are “discrete psychometric constructs 
that are topically related but otherwise independent of each other”. Our findings confirm this 
statement. 
 To our knowledge, few if any studies have identified the postoperative time when patients can 
expect stability in urinary, sexual, and bowel bother after curatively intended PCa treatment, and when 
“stable bother” can be predicted for the three treatment modalities. Unlike Malcolm et al. (152), in 
paper III we chose to calculate PBS-100 (instead of PBS-90) because the bother score of the UCLA-
PCI includes only five categories, which did not allow us to quantify recovery to 90% of the 
pretreatment bother score. 
 A limitations of paper III was that the UCLA-PCI questionnaire is not comprehensive enough 
regarding adverse hormonal effects, which can cause considerable symptoms (213). In retrospect, 
follow-up for 24 months after treatment can be criticized because some of the patients recruited early 
in the study, who received RAD with ADT for a total of 3 years, had just finished ADT treatment at 
their 24-month follow-up. 
 As with paper II, another limitation was the relatively large number of patients who were 
missed at inclusion. As mentioned in the general discussion and in the discussion of paper II, the daily 
routine at the hospital meant that it was difficult to approach all patients who were to undergo RALP. 
In retrospect, we might have circumvented this problem by mailing the information and the 
questionnaire to these same-day surgery patients. Such costly administrative experiences represent 
important learning for a later study. Our attrition analyses showed no significant differences in 
Gleason, T category, PSA level, and marital status between the included and omitted patients. 
However, we have no information about the psychosocial variables and comorbidities in the omitted 
patients, and we cannot ignore that this may reduce the external validity of our findings. 
 As mentioned in the discussion of paper II, information about the nerve-sparing procedure was 
not recorded accurately or consistently. To try to compensate for this, a more detailed definition of 
nerve sparing was used in paper III (73). Other studies have demonstrated an effect of nerve sparing 
on erectile function (137), and we cannot rule out the possibility that the nerve-sparing procedure 
affects sexual bother. 
 In retrospect, the use of medication should have been addressed more carefully in the 
questionnaires because some drugs influence sexual function. For example, beta-blockers can 
adversely affect sexual function (214). We should also have included questions about the use of 
medication for erectile dysfunction. 
 
56
 The strengths of paper III are the prospective design, the relatively large number of patients 
included, and the analysis of the three treatment modalities offered concurrently to patients not 
undergoing adjuvant or salvage systemic or local therapy within 24 months. To our knowledge, only 
one previous study has compared bother after surgery with bother after RAD without ADT (138) and 
no other studies have compared all three treatment modalities, RALP, RAD with ADT, and RAD 
without ADT. 
6. CONCLUSIONS OF THE THESIS 
Paper I 
 Overall adherence to the guidelines for curative treatment of PCa was high: 88% of the patients 
during period I were treated according to the 2003 EAU guidelines, and 80% in period II were 
treated according to NRH guidelines. Overly strict recommendations, such as age-based limits, are 
frequent reasons for nonadherence. 
 Authors of guidelines should be careful not to impose overly strict limitations in the guidelines. 
Rather, guidelines should allow room for the preferences of individual patients and physicians 
based on well-established clinical experience. The reasons for deviations from accepted guidelines 
for individual patients should be documented in the patient’s medical record. It is important that 
clinicians know the guidelines and the background for the guidelines (e.g., evidence grade A or D, 
etc.) because this is important information in the discussion with the patient. It should take more to 
deviate from a guideline based on level A evidence than on level D evidence.
 Adherence to guidelines should be monitored regularly. Because of the rapid development of new 
treatment techniques, guidelines should be revised regularly and frequently, and should include 
new evidence-based findings. 
Paper II 
 PBS-90 identifies the first postoperative time when, within a 24-month timeframe, the highest 
percentage of patients with almost complete recovery of pretreatment function has been reached. 
The GEE identifies the time at which the 24-month outcome can be predicted. Principally different 
patterns of AEs emerged after RALP and RAD without ADT. The principal dysfunctions were 
sexual and urinary functions for patients treated with RALP and bowel function for those treated 
with RAD. 
 Six months after RP or RAD without ADT and within a 24-month observation period, the 
percentage of patients with 90% recovery of their baseline function had become stable. The levels 
of dysfunctions at that time are associated with those at 24 months. 
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 The results of this prospective study should be considered during pretreatment counseling of 
patients with PCa who must choose their curative treatment by considering the risk of 
posttreatment AEs. The new knowledge about recovery and the ability to predict 24-month 
dysfunction could be incorporated into counseling and planning of posttreatment follow-up. 
Paper III 
 The standard curative treatment modalities for nonmetastatic PCa show distinct patterns for sexual, 
urinary, and bowel bother during the first 2 years after treatment. RALP patients reported mainly 
sexual and urinary bother whereas irradiated patients were bothered by bowel dysfunction. 
 The PBS-100 results showed that the percentage of patients with posttreatment typical bother 
stabilized between 3 and 6 months after treatment. The GEE showed that bother at 6 months was 
significantly associated with bother at 24 months. 
 Except for neuroticism, baseline psychosocial variables have little impact on urinary, bowel, and 
sexual bother. 
 Bowel and urinary bother levels were strongly correlated with their corresponding functions, 
whereas the correlation between sexual bother and function was weak. 
 The findings about the recovery of dysfunction-related bother and the discrepancy between sexual 
dysfunction and sexual bother are important issues to be communicated to the patients during pre- 
and posttreatment counseling. 
7. CLINICAL IMPACT AND FUTURE PROJECTS 
 In recent years, a number of national treatment guidelines have been designed in Norway for 
different tumor groups. However, adherence to these guidelines is rarely monitored. Based on our 
experience performing the research described in paper I, we recommend that adherence to 
guidelines should be monitored regularly and that guidelines should be updated regularly to include 
rapidly developing therapeutic improvements. Guidelines must allow room for individual decisions 
based on discussions between the patient and physician, and these decisions should be documented 
in the medical record. 
 The projected 10-year relative survival rate for all stage of PCa in Norway is about 78%, (5 year 
relative survival for localized PCa 97.3 %) (1) meaning that most these patients must live with the 
AEs for many years. The findings about the prevalence of, recovery from, and prediction of AEs 
described in papers II and III provide important information for improving patient–physician 
communication before treatment and during follow-up. Hopefully, these results will help answer 
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 As an increasing number of patients receive postoperative RAD or systemic ADT, the effects of 
multimodal treatment should be studied. 
 Registration of self-reported AEs should be a part of the electronic medical record to allow for 
regular monitoring of treatment. 
 This study highlights the importance of systematic data collection when new technologies are 
introduced into clinical practice, both to evaluate and to compare the benefits of a new technology 
in an unselected group of patients. 
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UCLA Prostatakreft index (UCLA-PCI)
med tilleggsspørsmål (SF-12 versjon)
Pasient nr:
        Oversettelse og tilleggsspørsmål er et samarbeid mellom
         Radiumhospitalet og Oslo Urologiske Universitetsklinikk,
                                               januar 2005
Dato for utfylling: . .
(Fylles ut av KKF)
Kryss av for behandling
Radikal prostatektomi
Kryoterapi
Strålebehandling uten hormoner
Strålebehandling med hormoner
Strålebehandling v/ N+ med hormoner
Brachyterapi + ekstern strålebehandling uten hormoner
Brachyterapi + ekstern strålebehandling med hormoner
Navnelapp
Registreringsskjema
Utfylt skjema fra lege og pasient sendes samlet til:
Kontor for klinisk forskning, v/ Bente Kvisgaard
Signatur av lege
UCLA Prostatakreft index (UCLA-PCI)
med tilleggsspørsmål (SF-12 versjon)
Pasient nr:
Dato for utfylling: . .
Hensikten med dette spørreskjemaet er å få rede på din helse generelt og hvordan din
prostatakreft og behandling for den påvirker din livskvalitet.
Vær snill å lese hvert spørsmål nøye før du svarer.  Hvis du er usikker  på hva du skal svare på
et spørsmål, så svar så godt du kan.  Husk at det er ingen riktige eller gale svar.
Dine svar på dette spørreskjemaet vil bli behandlet strengt konfidensielt, og de vil bare bli brukt
til forskning.  Informasjonen du gir vil bli bearbeidet sammen med svarene fra andre pasienter
som også fyller ut skjemaet, slik at det ikke blir mulig å finne tilbake til svarene fra
enkeltpersoner.
Spørreskjemaet er en norsk oversettelse av et skjema som er mye brukt internasjonalt, noe
som gjør at våre behandlingsresultater kan sammenlignes med resultatene i andre land.
Spørsmålene skal stilles til pasienter som gjennomgår flere ulike behandlinger, og noen
spørsmål er derfor ikke aktuelle for deg.  Vi ber deg likevel ta deg tid til å fylle ut skjemaet
fullstendig.
        Oversettelse og tilleggsspørsmål er et samarbeid mellom
         Radiumhospitalet og Oslo Urologiske Universitetsklinikk,
                                               januar 2005
Utfylling av Teleform skjema
1.  Bruk bare blå eller sort kulepenn (ikke blyant)
2.  Kryss innenfor rutene:
3. Skriv tallene slik:
4.  Skjemaet må ikke brettes (gir streker i skjemaet ved skanning)
1 2 3 4 5 6 7 8 9 0
X
1.   Hvilke av følgende passer best på ditt nåværende forhold?
Bor med kone eller samboer
Er i et fast forhold, men bor ikke sammen
Er ikke i noe fast forhold
2.   Hvor mye utdanning har du gjennomført?
Grunnskole eller mindre
Noe videregående eller yrkesskole
Gjennomført videregående eller yrkesskole
Noe på høgskolenivå
Gjennomført høgskole
Gjennomført universitetsutdannelse
3.   Har du eller har du hatt noen av følgende sykdommer eller tilstander?
a)  Sukkersyke (diabetes)
b) Hjerteinfarkt, hjertekrampe (angina)
c)  Hjerneslag
d)  Amputasjon
e)  Dårlig blodforsyning til beina
f)  Astma, kronisk bronkitt, pusteproblemer
g)  Magesår, irritabel tarm
h)  Nyresykdom
i)  Alvorlig depresjon
j)  Krampeanfall
k) Alkoholproblemer
l)  Stoffproblemer
m)  Tidligere sigarettrøyker
n)  Nåværende sigarettrøyker
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ja Nei
4.   Er du for tiden i inntektsgivende arbeid?
Ja, fulltid
Ja, deltid
Nei, men søker jobber
Nei, pensjonert
Nei, sykmeldt eller på attføring
Nei, uføretrygdet
UCLA-PCI
Demografiske og korte medisinske spørsmål
Pasient nr.: Dato for utfylling: . .
KKF, Radiumhospitalet, 2005
20666
Ja Nei
Spørsmålene nedenfor dreier seg om hvordan du vanligvis opptrer, føler og
handler.  Vennligst kryss av       for enten Ja eller Nei.  Svar hurtig og ikke
tenk for lenge over den nøyaktige meningen med hvert spørsmål.
1.   Er du forholdsvis livlig?
2.   Ville du bli oppskaket av å se et barn eller et dyr lide? Ja Nei
3.   Liker du å treffe nye mennesker? Ja Nei
4.   Blir dine følelser lett såret? Ja Nei
5.   Hender det ofte at du "går trøtt"? Ja Nei
6.   Liker du å spille andre et puss som av og til kan såre dem? Ja Nei
7.   Er du ofte bekymret? Ja Nei
8.   Er gode manerer og renslighet viktig for deg? Ja Nei
9.   Bekymrer du deg for at fryktelige ting kan skje? Ja Nei
10.  Tar du vanligvis selv det første skrittet for å få nye venner? Ja Nei
11.   Er du for det meste stille når du er sammen med andre? Ja Nei
12.   Liker du å komme til avtaler i god tid? Ja Nei
13.   Har du ofte følt deg trøtt og giddesløs uten grunn? Ja Nei
14.   Er det mange mennesker som forsøker å unngå deg? Ja Nei
15.   Klarer du å holde fart i et selskap? Ja Nei
16.   Bekymrer du deg lenge etter en pinlig opplevelse? Ja Nei
17.   Liker du å ha masse liv og røre rundt deg? Ja Nei
18.   Forteller folk deg en masse løgner? Ja Nei
UCLA-PCI
Eysenck Pasient nr.:
Dato for utfylling: . .
KKF, Radiumhospitalet, 2005

22663
Dette spørreskjemaet er utformet for å hjelpe oss til å forstå hvordan du føler deg.  Les hvert utsagn og sett
kryss   i ruten som best beskriver dine følelser den siste uka.  Fundér ikke for lenge på ditt svar; din
umiddelbare reaksjon på hvert spørsmål er sannsynligvis riktigere enn et svar som du har tenkt lenge på.
2. Jeg gleder meg fremdeles over ting jeg
      pleide å glede meg over
Avgjort like mye
Ikke fullt så mye
Bare lite grann
Ikke i det hele tatt
3. Jeg har en urofølelse som om noe
      forferdelig kommer til å skje
Helt sikkert og svært ille
Ja, men ikke så veldig ille
Litt ille, men det bekymrer meg ikke så mye
Ikke i det hele tatt
4. Jeg kan le og se det morsomme i situasjoner
Like mye som jeg alltid har gjort
Ikke like mye nå som før
Avgjort ikke så mye nå som før
Ikke i det hele tatt
 5. Jeg har hodet fullt av bekymringer
Veldig ofte
Ganske ofte
Av og til
En gang i blant
 6. Jeg er i godt humør
Aldri
Noen ganger
Ganske ofte
For det meste
 7. Jeg kan sitte i fred og ro og kjenne meg
     avslappet
Ja, helt klart
Vanligvis
Ikke så ofte
Ikke i det hele tatt
 8. Jeg føler meg som om alt går langsommere
Nesten hele tiden
Svært ofte
Fra tid til annen
Ikke i det hele tatt
 9. Jeg føler meg urolig som om jeg har
      "sommerfugler" i magen
Ikke i det hele tatt
Fra tid til annen
Ganske ofte
Svært ofte
10. Jeg har sluttet å bry meg om hvordan jeg ser ut
Ja, helt klart
Jeg bryr meg ikke så mye som jeg burde
Det kan nok hende jeg ikke bryr meg nok
Jeg bryr meg om utseendet like mye som jeg
11. Jeg føler meg rastløs som om jeg stadig må
       være i aktivitet
Uten tvil svært mye
Ganske mye
Ikke så veldig mye
Ikke i det hele tatt
12. Jeg ser med glede frem til hendelser og ting
Like mye som jeg alltid har gjort
Heller mindre enn jeg pleier
Avgjort mindre enn jeg pleier
Nesten ikke i det hele tatt
13. Jeg kan plutselig få en følelse av panikk
Uten tvil svært ofte
Svært ofte
Ikke så veldig ofte
Ikke i det hele tatt
14. Jeg kan glede meg over en god bok eller et
      radio eller et TVprogram
Ofte
Fra tid til annen
Ikke så ofte
Svært sjelden
 1. Jeg er nervøs eller anspent
For det meste
Ofte
Noen ganger
Ikke i det hele tatt
UCLA-PCI
HADS
alltid har gjort
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Vi vil gjerne vite om du har følt deg sliten, svak eller i mangel av overskudd den siste måneden.  Vennligst besvar ALLE spørsmålene ved å
krysse av         for det svaret du synes passer best for deg. Vi ønsker at du besvarer alle spørsmålene selv om du ikke har hatt slike
problemer. Vi spør om hvordan du har følt deg i det siste og ikke om hvordan du følte deg for lenge siden. Hvis du har følt deg sliten lenge,
ber vi om at du sammenlikner deg med hvordan du følte deg sist du var bra.  (Ett kryss på hver linje)
 1. Har du problemer med
at du føler deg sliten? Mindreenn vanlig
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
2. Trenger du mer hvile? Nei, mindre
enn vanlig
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
 3. Føler du deg søvnig eller
døsig? Mindreenn vanlig
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
 4. Har du problemer med
å komme igang med ting? Mindreenn vanlig
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
 5. Mangler du overskudd? Ikke i det
hele tatt
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
 6. Har du redusert styrke i
musklene dine? Ikke i dethele tatt
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
 7. Føler du deg svak? Mindre
enn vanlig
Som
vanlig
Mer enn
vanlig
Mye mer
enn vanlig
 8. Har du vansker med å
konsentrere deg? Mindreenn vanlig
Som
vanlig
Mer enn
vanlig
Mye mer
enn vanlig
  9. Forsnakker du deg i
samtaler? Mindreenn vanlig
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
10. Er det vanskeligere å
finne det rette ordet? Mindreenn vanlig
Ikke mer
enn vanlig
Mer enn
vanlig
Mye mer
enn vanlig
11. Hvordan er
hukommelsen din? Bedre ennvanlig
Ikke verre
enn vanlig
Verre enn
vanlig
Mye verre
enn vanlig
12. Hvis du føler deg sliten for tiden, omtrent hvor lenge har det vart?
Seks måneder eller merMellom tre og seks
måneder
Mindre enn tre
måneder
Mindre enn en uke
13. Hvis du føler deg sliten for tiden, omtrent hvor mye av tiden kjenner du det?
Hele tiden75% av tiden50% av tiden25% av tiden
UCLA-PCI
Fatigue (tretthet)
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Helsen din
UCLA-PCI
1.   Stort sett, vil du si at din helse er:
De første spørsmålene er om hvordan du ser på din egen helse, BÅDE RELATERT og IKKE RELATERT
til din prostatakreft.  Vi er klar over at andre sykdommer som du kan ha i tillegg til din prostatakreft
kan påvirke svarene dine.
Hvert spørsmål skal besvares ved å sette kryss        i ruten for det tallet som passer best for deg
(bare ett kryss).  Hvis du er usikker på hva du skal svare, vennligst svar så godt du kan.
å å
Utmerket
Meget god
God
Nokså god
Dårlig
De neste spørsmålene handler om aktiviteter som du kanskje utfører i løpet av en vanlig dag.  Er din
helse slik at den begrenser deg i utførelsen av disse aktivitetene nå?  Hvis ja, hvor mye?
2.   Moderate aktiviteter som å flytte et bord, støvsuge, gå en tur eller drive med hagearbeid
Ja, begrenser meg mye
Ja, begrenser meg litt
Nei, begrenser meg ikke i det hele tatt
3.   Gå opp trappen flere etasjer
Ja, begrenser meg mye
Ja, begrenser meg litt
Nei, begrenser meg ikke i det hele tatt
I løpet av den siste uken, har du hatt noen av følgende problemer i ditt arbeid eller i andre av dine
gjøremål på grunn av din fysiske helse?
4.   Du har utrettet mindre enn du hadde ønsket
5.   Du har vært hindret i visse typer arbeid eller andre gjøremål
Ja Nei
Ja Nei
I løpet av den siste uken, har du hatt følesesmessige problemer som har ført til vanskeligheter i ditt
arbeid eller i andre av dine daglige gjøremål (f.eks. fordi du har følt deg deprimert eller engstelig)?
6.   Du har utrettet mindre enn du hadde ønsket Ja Nei
7.   Du har utført arbeidet eller andre gjøremål mindre grundig enn vanlig Ja Nei

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8.   I løpet av den siste uken, hvor mye har smerter påvirket ditt vanlige arbeid (gjelder både arbeid utenfor hjemmet og
      husarbeid)?
Ikke i det hele tatt
Litt
Endel
Mye
Svært mye
De neste spørsmålene handler om hvordan du har følt deg og hvordan du har hatt det den siste uken.
For hvert spørsmål, vennligst velg det svaralternativet som best beskriver din situasjon.
Hvor ofte i løpet av den siste uken?
9.   Har du følt deg rolig og harmonisk?
Hele tiden
Nesten hele tiden
Mye av tiden
En del av tiden
Litt av tiden
Ikke i det hele tatt
10.   Har du følt deg full av tiltakslyst?
Hele tiden
Nesten hele tiden
Mye av tiden
En del av tiden
Litt av tiden
Ikke i det hele tatt
11.   Har du følt deg nedfor og trist?
Hele tiden
Nesten hele tiden
Mye av tiden
En del av tiden
Litt av tiden
Ikke i det hele tatt
12.  I løpet av den siste uken, hvor mye av tiden har din fysiske helse eller følelsesmessige problemer påvirket din sosiale
       omgang (som det å besøke venner, slektninger osv.)?
Hele tiden
Mesteparten av tiden
En del av tiden
Litt av tiden
Ikke i det hele tatt
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Urinfunksjon
Dette avsnittet omhandler din urinfunksjon.  Det er kun situasjonen de siste 4 ukene du skal ta i
betraktning.
13.   Hvor ofte har du hatt urinlekkasje i løpet av de siste 4 ukene?
Hver dag
Omtrent en gang i uken
Sjeldnere enn en gang i uken
Aldri
14.   Hvordan vil du beskrive din kontroll over blæretømmingen i løpet av de siste 4 ukene?
Total manglende kontroll (betydelig urinlekkasje)
Hyppig urinlekkasje
Dråpelekkasje av og til
Ingen lekkasje (full kontroll)
15.   Hvor mange trusinnlegg, bind eller bleier har du vanligvis brukt pr. dag for lekkasje i løpet av de siste 4 ukene?
Tre eller flere per dag
En - to per dag
Ingen
16.   Hvor stort problem har hver av de følgende vært for deg?
a)  Urinlekkasje evt. med våte benklær
Ikke noe problem
Veldig lite problem
Lite problem
Moderat problem
Stort problem
b)  Urinlekkasje som forstyrrer seksuell aktivitet
Ikke noe problem
Veldig lite problem
Lite problem
Moderat problem
Stort problem
17.   Hvor stort problem har du totalt sett hatt med urinfunksjonen de siste 4 ukene?
Ikke noe problem
Veldig lite problem
Lite problem
Moderat problem
Stort problem
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18.   Har du iløpet av de siste 4 ukene måttet skynde deg på toalettet pga. plutselig, kraftig vannlatingstrang?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
19.   Har du hatt urinlekkasje før du har kommet fram til toalettet?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
20.   Har du hatt urinlekkasje når du hoster eller nyser?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
21.   Har det hendt at du har lekket uten noen spesiell grunn og uten at du har følt vannlatingstrang?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
22.   Har du hatt urinlekkasje mens du sover?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
23.   Hvor ofte har du hatt en mindre urinlekkasje i trusen i løpet av de første minuttene etter at du har avsluttet vannlating?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
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24.   Tar det tid før urinen kommer ved vannlating?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
25.   Må du presse eller trykke for å tømme urinblæren?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
26.   Hvordan vil du beskrive kraften på strålen ved vannlating?
Aldri redusert
Av og til redusert (mindre enn en tredjedel av tiden)
Noen ganger redusert (i omtrent halvparten av tiden)
Oftest redusert (mer enn to tredjedeler av tiden)
Alltid redusert
27.   Hender det at urinstrålen stopper opp og starter igjen under vannlating?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
28.   Hvor ofte har du følt at blæren er ufullstendig tømt ved vannlating?
Aldri
Av og til (mindre enn en tredjedel av tiden)
Noen ganger (i omtrent halvparten av tiden)
Oftest (mer enn to tredjedeler av tiden)
Alltid
29.   Hvor ofte må du late vannet om dagen?
Hver time
Annenhver time
Tredjehver time
Fjerdehver time eller sjeldnere
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30.   Hvor mange ganger må du stå opp om natten for å late vannet i gjennomsnitt?
Aldri
En gang
To ganger
Tre ganger
Fire eller flere ganger
31.   Har du hatt svie eller smerte i forbindelse med vannlating i løpet av de siste 4 ukene?
Ikke i det hele tatt
Sjeldnere enn en gang i uken
Omtrent en gang i uken
Hver dag
32.   Har du hatt blod i urinen i løpet av de siste 4 ukene?
Ikke i det hele tatt
Sjeldnere enn en gang i uken
Omtrent en gang i uken
Hver dag
33.   Hvis du resten av livet måtte leve med de vannlatingsproblemene du har nå, hvordan ville du føle det?
Være meget godt fornøyd
Være fornøyd
Være for det meste tilfreds
Ha blandete følelser
Være for det meste utilfreds
Være misfornøyd
Ha det forferdelig
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Avføringsfunksjon
Dette avsnittet omhandler dine avføringsvaner og magesmerter.  Det er kun situasjonen de siste
4 ukene du skal ta i betraktning.
34.   Hvor ofte har du hatt plutselig, kraftig avføringstrang (følt at du skulle ha avføring uten at det kom noe) i løpet av
        de siste 4 ukene?
Mer enn en gang per dag
Omtrent en gang per dag
Mer enn en gang i uken
Omtrent en gang i uken
Sjelden eller aldri
35.   Hvor ofte har du hatt uvanlig tynn avføring eller  diaré i løpet av de siste 4 ukene?
Aldri
Sjelden
Omtrent halvparten av tiden
Vanligvis
Alltid
36.   Hvor store plager har du hatt med avføring i løpet av de siste 4 ukene?
Store plager
Moderate plager
Litt plager
Ingen plager
37.   Hvor ofte har du hatt krampaktige smerter i magen eller i underlivet i løpet av de siste 4 ukene?
Flere ganger om dagen
Omtrent en gang per dag
Flere ganger i uken
Omtrent en gang i uken
Omtrent en gang denne måneden
Sjelden eller aldri
38.   Samlet sett, hvor stort problem har avføringsfunksjonen vært for deg i løpet av de siste 4 ukene?
Stort problem
Moderat problem
Lite problem
Veldig lite problem
Ikke noe problem
39.   Hvor ofte har du hatt blod i avføringen i løpet av de siste 4 ukene?
Hver dag
Omtrent en gang i uken
Sjeldnere enn en gang i uken
Ikke i det hele tatt
KKF, Radiumhospitalet, 2005  Startskjema, side 7
37735
40.   Hvor ofte har du hatt slim i avføringen i løpet av de siste 4 ukene?
Hver dag
Omtrent en gang i uken
Sjeldnere enn en gang i uken
Ikke i det hele tatt
41.   Hvor ofte har du hatt ufrivillig lekkasje av avføring i løpet av de siste 4 ukene?
Hver dag
Omtrent en gang i uken
Sjeldnere enn en gang i uken
Ikke i det hele tatt
42.   Hvor mange truseinnlegg, bind eller bleier for voksne har du vanligvis brukt per dag for avføringslekkasje i løpet av
        de siste 4 ukene?
Tre eller flere per dag
En - to per dag
Ingen
43.   Har ditt avføringsproblem medført at du har måttet planlegge dine toalettbesøk i løpet av de siste 4 ukene?
Hver dag
Omtrent en gang i uken
Sjeldnere enn en gang i uken
Ikke i det hele tatt
44.   Har du vært plaget av at du ventet det skulle komme luft, men så kom det i stedet litt avføring i løpet av de siste 4 ukene?
Hver dag
Omtrent en gang i uken
Sjeldnere enn en gang i uken
Ikke i det hele tatt
45.   Hvis du resten av livet måtte leve med de avføringsproblemene du har nå, hvordan ville du føle det?
Være meget godt fornøyd
Være fornøyd
Være for det meste tilfreds
Ha blandete følelser
Være for det meste utilfreds
Være misfornøyd
Ha det forferdelig
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Seksualfunksjon
Det neste avsnittet om seksualfunksjon inneholder mange spørsmål av personlig karakter.  Vi
minner om at svarene på dette spørreskjemaet vil bli behandlet konfidensielt og vil bare bli brukt til
forskningsformål:  Vær snill å svare så ærlig som du kan om de siste 4 ukene.
46.   Hvordan vil du gradere dine evner vedrørende a, b og c nedenfor i løpet av de siste 4 ukene?
a)  Grad av seksuell interesse (lyst)
Svært dårlig
Dårlig
Rimelig
God
Svært god
b)  Evne til å få ereksjon (reisning)
Svært dårlig
Dårlig
Rimelig
God
Svært god
c)  Din evne til å få orgasme (klimaks)
Svært dårlig
Dårlig
Rimelig
God
Svært god
47.   Hvordan er vanligvis GRADEN av stivhet ved ereksjon?
Ingen ereksjon (reisning)
Ikke stiv nok til seksuell aktivitet
Bare stiv nok til onanering og forspill
Tilstrekkelig stivhet for samleie
48.   Hvor OFTE har du oppnådd ereksjon når det har vært ønskelig?
Aldri ereksjon når jeg har ønsket det
Mindre enn halvparten av tiden
Omtrent halvparten av tiden
Mer enn halvparten av tiden
Alltid ereksjon når det har vært ønskelig
49.   Hvor ofte har du våknet om morgenen eller natten med ereksjon?
Aldri
Sjelden (mindre enn 25% av tiden)
Ikke ofte (mindre enn halvparten av tiden)
Ofte (mer enn halvparten av tiden)
Veldig ofte (mer enn 75% av tiden)
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50.   Har du gjennomført samleie i løpet av de siste 4 ukene?
Nei
Ja, en gang
Ja, mer enn en gang
51.   Hvordan vil du karakterisere din evne til å fungere seksuelt de siste 4 ukene?
Svært dårlig
Dårlig
Rimelig
God
Svært god
52.   Har du brukt tabletter utskrevet av lege for å bedre seksuell funksjon (potens) i løpet av de siste 4 ukene?
Alltid
Oftest
Sjelden
Aldri
53.   Har du satt sprøyte/ injeksjon i penis for å få bedre ereksjon i løpet av de siste 4 ukene?
Alltid
Oftest
Sjelden
Aldri
54.   Hvordan vil du beskrive din evne til å gjennomføre samleie uten, eller eventuelt med tabletter eller sprøyter i
        løpet av de siste 4 ukene?
a)  Uten tabletter eller sprøyter
Ikke aktuelt
Ikke ereksjon, samleie ikke mulig
Samleie mulig i mindre enn halvparten av forsøkene
Samleie mulig ved de fleste forsøk
Samleie alltid mulig
b)  Med tabletter for potens (ikke sprøyter)
Ikke aktuelt
Ikke ereksjon, samleie ikke mulig
Samleie mulig i mindre enn halvparten av forsøkene
Samleie mulig ved de fleste forsøk
Samleie alltid mulig
c)  Etter bruk av sprøyter i penis
Ikke aktuelt
Ikke ereksjon, samleie ikke mulig
Samleie mulig i mindre enn halvparten av forsøkene
Samleie mulig ved de fleste forsøk
Samleie alltid mulig
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55.   Hvor stort problem totalt sett har din seksualfunksjon vært for deg de siste 4 ukene?
Ikke noe problem
Svært lite problem
Lite problem
Moderat problem
Stort problem
56.   Har du hatt smerter eller ubehag i forbindelse med orgasme/ utløsning?
Alltid
Oftest (mer enn halvparten av gangene)
Ganske ofte (omtrent halvparten av gangene)
Sjelden (mindre enn halvparten av gangene)
Aldri
KKF, Radiumhospitalet, 2005
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57.  Hvor stort problem, om noe, har hvert av de følgende vært for deg de siste 4 ukene?
a) Hetetokter
b) Ømme/ svulne bryster/ brystvorter
c) Tap av hår  på kroppen
d) Følt deg nedstemt
e) Manglet energi
f) Vektøkning
g) Vektreduksjon
  Intet
problem
 Veldig lite
  problem
   Lite
problem
 Moderat
 problem
  Stort
problem
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